Renal manifestations of human immunodeficiency virus in the era of antiretroviral treatment in South Africa. by Assaram, Shirelle.
  
 
 RENAL MANIFESTATIONS OF HUMAN 
IMMUNODEFICIENCY VIRUS IN THE ERA OF 
ANTIRETROVIRAL TREATMENT IN SOUTH AFRICA 
 





A dissertation submitted to the College of Health Sciences, University of KwaZulu-Natal, in 

















Background:   
Sub-Saharan Africa carries the global burden of human immunodeficiency virus (HIV) infection.  
Renal disease is a well-recognized and closely associated complication of HIV infection.  The burden 
of kidney disease in Africa is aggravated by poor socio-economic factors and by the lack of access to 
healthcare and to resources.  Most of what is known regarding HIV related kidney disease has come 
from research done in high income countries.   
Aim:  Demonstrating the current stance on renal manifestations of HIV in South Africa in the era of 
antiretroviral treatment (ART).   
Study design:  This is a cross-sectional study. Mixed data acquisition methods using qualitative and 
quantitative research approaches were applied in this study in order to achieve the objectives. These 
included a systematic scoping review and a retrospective chart review. 
Data collection and analysis:  The systematic scoping review began with a database search of 
published literature based on studies conducted in South Africa.  The following databases:  Google 
Scholar, PubMed, Medline, Cochrane Library, Worldcat.org and EBSCO host were searched to obtain 
relevant literature. We formulated a standardized data extraction table according to the PICO model. 
We presented a narrative account of the findings by performing a thematic content analysis of the 
included studies.  For the chart review we extracted data from medical records of all new patients 
initiated on ART from April 2010 to December 2013. The sample size was 350 patient records. We 
collected data at baseline (pre-ART) and then at 6, 12, 18 and 24 months on ART.  Descriptive 
statistics were used to describe the characteristics of HIV-related renal manifestations at the King 
Edward VIII Hospital ART clinic. 
Results:  The results of the systematic scoping review showed that normal renal function occurred in 
28.4% to 79% of patients, mild renal impairment occurred in 19% to 57.1% and moderate renal 
impairment in 2% to 14.4%. Only 1.3% of patients had severe renal impairment.  Both the Cockcroft-
Gault equation (after correcting for bias) and the 4-variable Modification of Diet in Renal Disease 
equation (without the ethnicity factor for African Americans) have been validated for the estimation of 
glomerular filtration rate (eGFR) in Black South Africans. HIV-associated nephropathy was the most 
prevalent histology seen (57.2%). Older age, a lower CD4 count, a low haemoglobin and a detectable 
viral load were linked to renal impairment. Renal function improved in the first year of commencing 
ART. 
With regards to the chart review, 64% of the cohort was female, 99% were African and the mean age 
was 36.9±9.7 years.  At baseline, 10 patients had hypertension, 6 had diabetes, 61 were co-infected with 
tuberculosis (TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorized as 
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overweight and 19.4% obese. Regarding baseline renal function, the majority of the patients had a 
normal renal function: 90.4% (95% confidence intervals (CI):86%-93%); 7.0% (CI:5%-10%) had 
moderate renal impairment; 1.3% (CI:0%-3%) had severe renal impairment; and 1.3% (CI:0%-3%) had 
kidney failure.  The risk of renal impairment increased by 1.06 (CI: 1.03 – 1.10) times as BMI increased 
by one unit. The association of hypertension (HPT) with abnormal renal function was found to be 
insignificant, p>0.05.  The majority of patients were initiated on tenofovir disoproxil fumarate (TDF) 
(90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) or 
nevirapine (NVP) (43.4%).   
 
Conclusion:  The scoping review highlights age, CD4 cell count, haemoglobin, detectable viral load as 
factors associated with renal impairment and the improvement in renal function with use of ART.  As 
more patients are started on ART according to the ‘test and treat’ approach to HIV prevention and 
management in South Africa, it is possible that the benefit may extend to the burden of kidney disease, 
however, hypertension, diabetes and obesity may reduce these benefits. The chart review found a low 
prevalence of baseline renal impairment in HIV-infected ART-naïve outpatients. An improvement in 
renal function after the commencement of ART has been demonstrated among this population.  
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DEFINITION OF TERMS  
 
Chronic kidney disease - The presence of 3 months or more of kidney damage or a glomerular filtration 
rate (GFR) of <60mL/min/1.73m2 irrespective of cause.  Kidney damage can be detected by the presence 
of albuminuria, defined as albumin-to-creatinine ratio >30mg/g in two of three spot urine specimens. 
Hypertension - Persistent elevation of blood pressure (BP) ≥ 140/90.  Repeat measurements should 
be performed on 3 separate occasions within a period of 2 months, to determine whether a diagnosis of 
hypertension is valid. 
Incidence – Incidence is the rate of new (or newly diagnosed) cases of the disease.   It is generally 
reported as the number of new cases occurring within a period of time.   
Prevalence - Prevalence is the actual number of cases alive with the disease either during a period of 
time (period prevalence) or at a particular date in time (point prevalence). It is most meaningfully 
reported as the number of cases as a fraction of the total population at risk.
 




ACRONYMS AND ABBREVIATIONS 
 
AIDS Acquired immunodeficiency syndrome 
ARF Acute renal failure 
ART Antiretroviral treatment 
ATN Acute tubular necrosis 
BP Blood pressure 
CG Cockcroft-Gault 






Estimated glomerular filtration rate 
FDC 
GFR 
Fixed dose combination 
Glomerular filtration rate 
HAART Highly active antiretroviral treatment 
HIV Human immunodeficiency irus 
HIVAN HIV-associated nephropathy 
HPT Hypertension 
HSRC Human Science Research Council 
MDRD 
MMAT 
Modification of diet in renal disease 
Mixed methods appraisal tool 
NRTI Nucleoside reverse transcriptase inhibitor 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
NSP 
NVP 
National Strategic Plan 
Nevirapine 
PI Protease inhibitor 








World Health Organization 
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CHAPTER 1: INTRODUCTION  
 
1.1. Background  
Human immunodeficiency virus (HIV) infection affects multiple organs and its manifestations in the 
kidney are variable (1).  The incidence of kidney disease is higher in low income countries than in 
high income countries (2).   Most of the data regarding renal involvement in HIV infection has come 
from research done in high-income countries.  However, the presentation of renal disease in Africa is 
different to that reported in high income countries (3).  
In high income countries the burden of the cost of dialysis is carried by the government e.g. the 
Medicare Chronic Kidney Disease  program in the United States which allows for close to universal 
access to treatment for chronic kidney disease (CKD) (4).  The availability and accessibility of 
dialysis and transplantation in Africa varies and is limited due to the high costs involved and the 
scarcity of donors (2).  Also in the United States, due to the production and early increased access to 
antiretroviral treatment (ART), the incidence of HIV-associated renal disease progressing to end stage 
renal disease has remained steady or has decreased (5).  On the other hand, Mayosi et al. reports for 
instance a 67% increase in deaths related to nephritis or nephrosis in South Africa from 1999 to 2006 
(6).  The increase in the prevalence of kidney disease may be causally linked to the rising burden of 
HIV infection and HIV related kidney disease in South Africa (3).   Those affected are mainly young 
black adults who present with severe opportunistic infections mainly tuberculosis (TB) and who have 
no past history of illness (3).  The estimated number of nephrologists per million population in the 
United Kingdom is 5.3 (7)  as opposed to Nigeria and South Africa where the number of 
nephrologists per million population is estimated to be 0.6 and 1.1, respectively. This suggests that 
Africa has the lowest number of nephrologists per million population globally (8, 9). The third leading 
cause of end stage renal disease among Black American men aged 20 to 64 years old was found to be 
HIV associated nephropathy (HIVAN) (10, 11).  The peak prevalence of CKD in Nigeria is between 
30 and 50 years of age (12, 13).  HIVAN is the most common pattern of renal disease seen in South 
Africans based on renal biopsies performed on HIV infected individuals in Cape Town between 
January 2000 and December 2009 (8).  The early detection of acute and chronic renal failure is 
delayed by the lack of routine screening of renal function due to overburdened clinics and laboratory 
facilities in the public health sector (3) and by the limited access to renal biopsies in parts of Africa 
(8).    
Access to health care including to ART varies in Sub-Saharan Africa due to socio-economic and 
political factors (1, 3).  Therefore, a study in a single country in Sub-Saharan Africa cannot be used to 
make deductions about the epidemic in the entire region (1).  The data on the incidence, prevalence 




and causes of HIV-related renal disease in Africa thus far have been unreliable because there have 
been no large epidemiological studies in this region (3, 8).  Recently, several reports have emerged 
which emphasize the lack of knowledge about renal disease in Africa and the need for further research 


























1.2. Problem statement  
Most of what is known regarding the renal involvement in HIV infection has come from research 
done in high income countries.  At some stage of their HIV infection, 10% of patients will develop 
HIV-related renal disease, according to data from the United States (14).  Extrapolating this to the 
South African context, suggests that an estimated 650 000 patients may develop HIV-related renal 
disease (14).  A large burden of  CKD would place immense pressure on the resource strained health 
system (15).  There has been an increase in mortality in South Africa related to CKD (6).  Early 
detection of renal disease and quick referral to a nephrologist is crucial in the management of the 
disease but a lack of resources and finances hinders this process in low income countries such as 
South Africa (15).  Although Sub-Saharan Africa carries the global burden of HIV infection, there is a 
lack of research in this region particularly with respect to HIV-related kidney disease (16).  Mapping 
published peer reviewed evidence and demonstrating the current stance on renal manifestation of HIV 
in South Africa in the era of ART could help identify the research gaps and novel ideas for future 
research. This could also produce evidence to guide health policy makers and implementer of health 
interventions on the most appropriate intervention for reducing renal manifestations of HIV in high 
disease burdened settings.  
1.3. Research questions 
Main research question  
What are the renal manifestations of HIV infection in South Africa in the era of ART? 
Specific research questions  
1. What is the research gap on the renal manifestations of HIV infection in South Africa in the 
era of ART? 
2. What is the current pattern of HIV-related renal manifestations reported in South Africa in the 






1.4. Aims and objectives of this study 
Main aim 
Demonstrating the current stance on renal manifestations of HIV infection in South Africa in the era 
of ART.  
Objectives 
1. To conduct a scoping review in order to identify the literature available on the renal 
manifestations of HIV in South Africa in the ART era.    
2. To conduct a retrospective chart review focussing on the following renal manifestations: 
 Change in estimated glomerular filtration rate (eGFR) from baseline to 24 months on 
ART 
 Change in blood pressure (BP) from baseline to 24 months on ART 
 Urine dipstick abnormalities documented in patients who had the test done 





1.5. Overview of this thesis 
This thesis consists of four chapters (including the current chapter): 
Chapter 1: This chapter presents the background, aim, objectives and significance of the study as 
well as providing a general outline of the thesis and its structure and the literature review and 
methodology.  
Chapter 2: This chapter presents the results of the systematic scoping review, aimed at investigating 
the renal manifestations of HIV in South Africa in the era of antiretroviral treatment (ART). The 
manuscript is presented in the form of a journal article entitled ‘HIV Renal Manifestations during the 
Antiretroviral Era in South Africa: A Systematic Scoping Review’.  This manuscript is currently 
under review at the BMC: Systematic Reviews Journal.  
Chapter 3: This chapter presents a retrospective chart review aimed at determining the risk factors 
and co-morbidities associated with renal impairment in an HIV-cohort to influence changes in policy 
and to guide future research. The chapter is presented in the form of a manuscript entitled: ‘Risk 
Factors and Co-Morbidities Associated with Changes in Renal Function among ART-naïve Adults in 
South Africa: A Chart Review’. The manuscript is currently under review at the South African 
Journal of Infectious Diseases.   
Chapter 4: This chapter is a discussion of study findings, strengths and limitations as well as a 
conclusion which contains some observations on the findings of this study, suggests future plans and 





1.6. Literature Review: Renal manifestations of HIV in South Africa 
 
1.6.1 Introduction 
Tackling the HIV and acquired immunodeficiency syndrome (AIDS) pandemic is the world’s most 
challenging public health issue (17).  Thomas Quinn described HIV/AIDS as “our modern day 
plague” (18).  In 2003, two thirds of the worlds’ people living with HIV were from Africa (17). The 
early stages of the epidemic in South Africa was limited to a few hundred cases among men who had 
sex with men and recipients of unsafe blood transfusions (19).  However, heterosexual transmission 
came to the forefront in the early 1990’s and the epidemic grew exponentially, extending to new-
borns and children through perinatal transmission (19).  The government at the time was subjected to 
intense criticism both locally and internationally for the denial of the causal relationship between HIV 
and AIDS (20).  In 2006, 34% of AIDS related deaths globally occurred in South Africa (21).  South 
Africa had the highest number of people living with HIV worldwide, estimated at 5.3 million as of 
December 2007 (10, 22).   
The National HIV/AIDS and Sexually Transmitted Infections (STI) National Strategic Plan (NSP) 
was implemented to tackle this epidemic. The primary objectives of this plan were to reduce HIV 
incidence by 50% and to expand the availability and access of ART to 80% of the population who 
required it (22).  An amount of R8.4 billion was budgeted in 2010-2011 for the expansion of the ART 
and Prevention of Mother to Child Transmission (PMTCT)  programmes, for the promotion of HIV 
and tuberculosis (TB) treatment integration and for greater investments in HIV prevention (23).  For 
the ART rollout in South Africa to reach full circle, an understanding of patient knowledge, attitudes 
and behaviours was essential because cultural factors can influence attitudes toward medication and 
health care practices (24, 25). Between August and October 2002, Nachega et al. conducted such a 
study in Soweto, South Africa and revealed good knowledge (averaging 86%) of the study population 
about HIV/AIDS (24).  The media plays a vital role in education and awareness of the disease and this 
needs to be continually reinforced.  However, the low rate of disclosure of HIV status to sexual 
partners, family and friends suggests that HIV/AIDS related stigmatization is rife and could play a 
role in impeding access to ART and affect compliance to ART (25).    
According to the Human Sciences Research Council’s (HSRC’s) National HIV Prevalence, Incidence 
and Behaviour Survey, the number of South Africans infected with HIV increased from 10.6% in 
2008 to 12.2% in 2012 taking the total number of people infected with HIV in South Africa to 6.4 
million in 2012 (26). The increased prevalence of HIV in 2012 can be contributed to a combination of 
the effects of new infections and a successful ART programme (resulting in decreased mortality 




incidence rate in females aged between 15 to 24 years of age being 3.1% as opposed to their male 
counterparts at 1.3% (in 2012) (27).  The population knowledge on the basics of HIV/AIDS decreased 
from 2008 to 2012 suggesting a shift in the holistic management of HIV to biomedical interventions 
such as ART and less on the social and behavioural aspects (26).  A domino effect is evident in the 
increase in risk seeking behaviour and the resultant high rate of new HIV infections in 2011. Sub-
Saharan Africa accounted for 71% of new infections in adults and children worldwide (27).  In 2015 
the HIV prevalence rate in South Africa was estimated at 7 million people living with HIV according 
to the Joint United Nations Programme on HIV/AIDS (UNAIDS), with 19.2% of adults aged 15 to 49 
years being HIV infected (28).  In this review,   the ART regimes, renal disease and renal 
manifestations of HIV infection with a specific focus on South Africa will be discussed.  
1.6.2 ART in South Africa   
It has been globally acknowledged that combination Antiretroviral Treatment (ART) improves the 
quality of life for infected individuals, reduces opportunistic infections and AIDS related mortality 
(29). There is growing scientific evidence that supports the use of early ART for both prevention of 
HIV transmission and clinical care. 
In 1983 the first case of AIDS was diagnosed in South Africa (19). The National ART programme in 
South Africa was launched in April 2004 (30, 31).  This delay in access to ART for the many infected 
South Africans resulted in the death of more than 300 000 people living with HIV (19).  Initially 
South Africa had difficulty procuring ART for its population infected with HIV due the costs involved 
(24, 32).  Wood et al. in their study in 2000 found that the cost of treating 25% of HIV infected South 
Africans with triple ART would be more than $19 billion (32).  This was soon rectified as a result of a 
combination of reduction in drug prices, private donations, the availability of generic drugs and the 
establishment of the Global Fund to Fight AIDS, Tuberculosis (TB) and Malaria (24).  
The South African ART guidelines are based on the World Health Organization (WHO) guidelines 
which has two treatment regimens: a first line regimen that includes two nucleoside reverse 
transcriptase enzyme inhibitors (NRTI) with a non-nucleoside reverse transcriptase enzyme inhibitor 
(NNRTI); and a second line regimen that contains two NRTI’S with a protease enzyme inhibitor (PI) 
(31).  Stavudine (D4T) was the NRTI widely used in the first line as part of the 2004 ART guidelines 
(31).  This drug was implicated in causing peripheral neuropathy, hyperlactataemia and lipodystrophy 
(33, 34). Boulle et al.’s study found that almost all drug substitutions due to drug toxicity in patients 
on a longer duration of ART, occurred in patients who were on D4T (33).  In April 2010, tenofovir 
replaced D4T as the NRTI in first line treatment (35).  On 1 April 2013, tenofovir in the form of a 
fixed dose combination (FDC) tablet was made universally available (36).  All patients on D4T were 
changed to the FDC tablet and ART naïve patients were initiated on FDC as per the national 




eligible for ART (37).  The number of patients who started ART in 2010/2011 was in excess of the 
number of people who became eligible to receive ART over the same period, thereby exceeding the 
targets set in the 2007-2011 NSP (37).  In 2012, the number of HIV infected people on ART in South 
Africa increased to 31.2% from 16.6% in 2008 (26).   
The other notable change in the guidelines over the years has been the CD4 count threshold for 
initiation of ART.  This was initially set at a CD4  count < 200µl in 2004 (31) and was increased to a 
CD4 count of ≤ 350µl in 2013 (36).    Granich et al. proposed that by expanding ART to CD4 < 
500µl, there would be a significant decrease in death, disability and expenditure on HIV/AIDS over 
40 years, an assumption based on a well-run ART programme (38).  This supports South Africa’s 
decision to adopt this policy and expand its ART programme to include patients with a CD4 count ≤ 
500µl (39).  As of September 2016, South Africa has adopted the WHO policy and has initiated all 
HIV infected individuals on ART irrespective of CD4 count (40).  This will help ensure that the South 
African ART programme  reaches targets set by the Joint United Nations Programme on HIV/AIDS to 
have 90% of all people tested for HIV, treated and virologically suppressed by 2020 (40).  Currently, 
South Africa has the largest ART programme in the world. 
1.6.3 Renal disease in the general population 
Worldwide the incidence of CKD is increasing at an annual growth rate of 8% (2).  CKD is defined as 
the presence of 3 months or more of kidney damage or an eGFR of <60mL/min/1.73m2 irrespective of 
cause (41).  eGFR can be calculated from calibrated serum creatinine and estimated equations such as 
the Modification of Diet in Renal Disease (MDRD) and Cockcroft-Gault (CG) equations which have 
been suggested to most closely approximate GFR in many African populations (41).   
South Africa is experiencing a double burden of disease with an increase in infectious diseases 
namely HIV/AIDS and TB along with an increase in non-communicable diseases such as 
hypertension (HPT), diabetes and cancer (6).  The risk factors for renal disease include communicable 
diseases e.g. HIV, infectious glomerulonephritis, schistosomiasis, non-communicable diseases such as 
HPT, diabetes and the use of traditional/herbal medication (42).  In their systematic analysis, Stanifer 
et al. found that CKD is a prevalent and potentially growing disease in Sub-Saharan Africa with 24% 
of hypertensives, 18.9% of diabetics and 10% of HIV infected patients having co-morbid chronic 
kidney disease (42).  HPT was the most common cause of end-stage renal disease in Black South 
Africans (43).  As per the South African Hypertension Guidelines, HPT is defined as a persistent 
elevation of blood pressure (BP)  ≥ 140/90 (44).  In South Africa in the year 2000, elevated BP was 





1.6.4 Renal manifestations of HIV in South Africa 
Fabian et al. described the clinical spectrum of renal disease seen in the course of HIV infection, as 
acute renal failure (ARF), electrolyte disturbances, intrinsic renal diseases e.g. co-morbid 
hypertension or diabetes mellitus and the group of HIV-associated glomerulonephropathies that may 
present with acute or chronic renal failure (46).  It is this group of glomerulonephropathies that 
contribute to the burden of CKD in HIV infection (46). 
Due to the large number of people infected and living with HIV in South Africa, the prevalence of 
CKD has increased (3).  At the Groote Schuur Hospital in Cape Town, South Africa, acute dialysis for 
HIV infected patients has become the most common indication for acute dialysis since January 2009 
(3).  The commonest cause of ARF in HIV infected patients is acute tubular necrosis secondary to 
sepsis, hypotension, dehydration or nephrotoxic drugs (3, 46).  Although ARF is potentially reversible 
with treatment, it carries a high mortality in the HIV population (11).  Morbidity from acute kidney 
injury is significant in black communities where HIV infected individuals seek the herbal treatment 
offered by traditional healers to assist them with AIDS related symptoms (3).   
In April 2010, the National ART programme in South Africa added tenofovir disoproxil fumarate 
(TDF) to the first line ART regimen (35).  TDF is excreted from the kidneys by glomerular filtration 
and active proximal tubular secretion and it can accumulate in the proximal tubular cells causing renal 
toxicity and renal failure (47).  It is therefore now imperative for all patients to be screened for renal 
dysfunction prior to starting ART, as any patient with pre-existing renal impairment would need 
alternative ART (35, 48).  The recent South African ART guidelines recommend doing a serum 
creatinine and creatinine clearance at baseline (prior to ART initiation) and then at 3 months, 6 
months, 12 months and annually thereafter for patients on TDF (35).   
Ultrasound to assess kidney size are available at most public hospitals in South Africa but renal 
biopsy facilities are limited to tertiary level institutions (3).  In a retrospective review by Gerntholtz et 
al. of 104 renal biopsies performed at Chris Hani Baragwanath Hospital in South Africa, classic 
HIVAN was found in 30% of the reviewed biopsies while about 20% were classified as “HIV 
immune complex kidney disease” (16).  This emphasizes the key role of renal biopsy in diagnosing 
HIV-associated renal disease, as only one third of the biopsies met the criteria for classic HIVAN (1).  
The lack of resources for renal biopsy precludes many patients from accurate diagnosis and proper 
treatment.   
The data from another study in South Africa, Han et al. suggested that HIVAN is possible in patients 
without overt nephrotic syndrome and in patients who have only microalbuminuria. Therefore 
microalbuminuria can be considered an early marker of HIVAN (10). The data on urinary screening 




outpatients, and routine urinary screening of all new patients at ART clinics should be standard 
practice (49).  Stanifer et al. showed that the prevalence of proteinuria when measured in people with 
HIV, HPT or diabetes is substantial. However the best method of urine protein detection is unknown 
(42).    
1.6.5 Discussion 
The HIV prevalence in children under 14 years old has declined over the past decade suggesting the 
success of the PMTCT programme (26, 50).  Mayosi et al. reported that mortality related to 
HIV/AIDS has declined by 20% in adults and 43% in children respectively and life expectancy has 
increased by 6 years as a result of the successful ART programme in South Africa (51).  South Africa 
has made significant progress with the ART programme since its implementation in 2004. The longer 
life expectancy on ART has implications for other chronic diseases, the burden of which will surely 
increase.  Until recently, the MDRD and CG equations to estimate GFR had not been validated in the 
South  African population or in HIV infected patients (1, 42).  This is important to note as GFR can be 
affected by diet and creatinine clearance can be altered by factors such as intake of meat and protein, 
muscle mass, medication and concurrent illness (important factors for patients in sub-Saharan Africa) 
(1).  The extensive rollout of TDF, a potentially nephrotoxic drug, in first line ART in South Africa 
implies aggressive screening for baseline renal dysfunction and continued renal function monitoring 
whilst on TDF.  However, access for patients to services such as renal ultrasound, renal biopsy and 
nephrology assessment is limited. 
1.6.6 Conclusion 
The increased burden of HIV infection and other non-communicable diseases, will require the 
integration of the care of both communicable and non-communicable diseases.  Improved urine 
diagnostics that are cheap and accessible to even rural areas are needed to detect renal dysfunction 
early so that potentially nephrotoxic ART can be avoided and patients can be timeously referred to 
nephrologists/CKD clinics.  Dedicated CKD clinics should be established and accessible to patients in 
rural and urban areas to access specialised services e.g. renal biopsy and dialysis.  More research is 
necessary to determine the association between baseline renal insufficiency and ART outcomes in 
patients on TDF.    
More patients on ART will probably result in a further increase in chronic disease in South Africa, 
mainly CKD, hypertension and diabetes.  The impact of this burden of chronic disease on the already 
resource strained healthcare system is not known.  However, with a lack of dedicated CKD clinics and 
specialist renal services particularly in the rural settings, as well as a deficiency in knowledge on the 




1.7. Methodology: Renal Manifestations of HIV in the era of ART in South Africa 
 
Theoretical Framework 
We considered the various systematic approaches available for reviewing published literature and 
chose to undertake a systematic scoping review of published literature as the best method to map the 
renal manifestations of HIV infection in South Africa in the era of ART. Scoping review methodology 
is particularly useful for examining a broadly covered topic to comprehensively and systematically 
map the literature and identify key concepts, theories, evidence, or research gaps. Unlike systematic 
reviews or meta-analyses, scoping reviews do not narrow the parameters of the review to research 
trials or require quality assessment. It is rigorous and methodical in its approach to examining the 
extent, range and nature of research activity in a particular field while encompassing both empirical 
and conceptual research with broadly framed questions (52). Arksey and O’Malley’s scoping review 
framework outlines a five stage approach (53) with each stage listed below: 
 Stage One - Identifying the research question:  maintain a broad scope to research questions 
to summarize a breadth of evidence. 
 Stage Two - Identifying relevant studies:  breadth and comprehensiveness of scoping studies 
are important and must be balanced with the feasibility of resources. 
 Stage Three - Study selection:  entails post hoc inclusion and exclusion criteria based on the 
research question and new information on the subject through reading the studies. 
 Stage Four - Charting the data:  a data-charting form is developed for use to extract data from 
each study.  A ’narrative review’ or ‘descriptive analytical’ method is used for data 
extraction. 
 Stage Five - Collating, summarising and reporting the results: this involves a descriptive 
numerical summary and a thematic analysis. 
 
We have adapted the Arksey and O’Malley’s conceptual framework to suit our study.  The broad 
nature of the research question can create a deficiency in the clarity, direction and focus required to 
inform subsequent stages of the research process such as study inclusion (54).  Levac et al. 2010 
suggest combining the broad research question with clear articulation considering the concept, target 
population and health outcomes of interest to clarify the focus of the scoping study and establish an 
effective search strategy (54).  This is the approach we chose to adopt to assist our search strategy.  
We assembled a scoping review team to enhance Stage 2 by providing the methodological and context 
expertise required when making decisions regarding breadth and comprehensiveness.  In Stage 3 of 




other researchers found a multidisciplinary team approach more practical and vigorous in study 
selection (54, 55) as did we.  We developed a data extraction table according to the patient, population 
or the problem, intervention, comparison and outcome (PICO) model for clinical questions (56).  Two 
reviewers performed a quality assessment of the included studies using the mixed methods appraisal 
tool (MMAT) for mixed methods studies to evaluate the risk of bias (57).  In our scoping review study 
we performed thematic content analysis to identify patterns of renal manifestations in the included 
studies.  We chose to replace Stage 6 of Arksey and O’Malley’s framework which is the consultation 
with major key holders with a retrospective chart review.  We believed that the chart review would 
provide a higher quality of evidence as opposed to the consultation process which provides mainly 
subjective data.  The systematic scoping review will provide a broad overview and will highlight key 
concepts and deficiencies that will guide the chart review (58).   
The retrospective chart review uses existing data (medical records) that have been documented for 
reasons other than research (59).  Conducting a chart review is an inexpensive method of analysing 
readily accessible data. It allows for the study of rare occurrences and it facilitates the formation of 
hypotheses which can be tested prospectively(58).   
Study Design  
Mixed data acquisition methods using qualitative and quantitative research approaches were applied 
in this study in order to achieve the objectives. These were a systematic scoping review and a 
retrospective chart review. 
Study setting 
We assessed literature on the renal manifestations of HIV infected patients in South Africa.  The chart 
review was that of patients attending the ART clinic in King Edward VIII Hospital in Durban. 
 
1.7.1.  Objective 1:  To conduct a scoping review in order to identify the literature available on 
the renal manifestations of HIV infection in South Africa in the ART era. 
 
Criteria for considering studies for this review: 
 HIV infected patients in South Africa only with evidence of renal manifestations 
 Studies published from 2004 to 2015 
 Adult patients (≥18 years old) with evidence of renal manifestations 




 Articles on South African data only  
 
Exclusion Criteria:  
 Patients <18 years of age 
 Literature from outside South Africa 
 Non-English literature 
 Pregnant females with renal disease 
 
Search methods for identification of studies 
The study began with a database search of published literature based on patients in South Africa.  We 
developed a list of primary and secondary search terms along with filtering methods.  The primary 
search terms related to the kidney specifically (i.e. kidney, renal, nephrology).  The secondary terms 
were manifestations, renal failure, complications, South Africa, antiretroviral treatment, proteinuria, 
glomerular filtration rate and hypertension.  In order to direct the search to our research question, we 
used the filtering method which included the data range (2004 to 2015), human subjects, English 
language and adult patients (≥18 years old).  MESH terms were also used. 
Electronic search 
We made use of the following databases:  Google Scholar, PubMed, Medline, Cochrane Library, 
Worldcat.org and EBSCO host. 
Data source and analysis 
The research team formulated the search strategy to be implemented and two reviewers independently 
perused eligible studies for trial study selection. Various publications, including academic journals on 
the subject were used to collect the relevant data. Information was gathered from studies that included 
randomized controlled trials, non-randomized controlled trials, observational studies, review articles, 
case reports and systematic reviews.  Only literature published from the year 2004 to 2015 was used 
for this review.  
Selection of studies 
This occurred in 2 stages.  First one reviewer conducted a comprehensive screening of titles and 
decided on eligibility based on the inclusion and exclusion criteria.  For example, titles stating 
research carried out in countries other than South Africa were excluded.  If the reviewer was uncertain 
of the eligibility of a title, it was not excluded but rather carried on to the next stage of the selection 




removed.  In the second stage of study selection, 2 independent reviews of the titles and abstracts 
using inclusion and exclusion criteria were undertaken.   Where differences of opinion arose, a third 
reviewer was involved to reach consensus.  The study selection procedure is illustrated using a 
PRISMA chart. 
Charting the Data 
We formulated a standardised data extraction table according to the PICO model.  The table included 
bibliographic details, study design and setting, sample size, aim of the study, interventions, 
comparisons, outcomes and conclusions.  Two reviewers performed a quality assessment of the 
included studies using the mixed methods appraisal tool for mixed methods studies to evaluate the 
risk of bias (57). 
Collating, summarizing and reporting results 
We presented a narrative account of the findings by performing a thematic content analysis on the 
extracted literature.  Results were structured into the following themes: urine analysis, estimated 
glomerular filtration rate, renal biopsy, risk factors for renal dysfunction and clinical and histological 
responses to ART.  The findings were scrutinised in relation to the overall aim of the study.  
Conclusions were drawn and recommendations for future research and clinical advancement were 
suggested. 
 
1.7.2. Objective 2: To conduct a retrospective chart review focussing on the following renal 
manifestations: 
 Change in GFR from baseline to 24 months on ART 
 Change in BP from baseline to 24 months on ART 
 Urine dipstick abnormalities in patients who had the test done 
 Risk factors and co-morbidities associated with abnormal renal function. 
 
Data sources 






We selected medical records of all new patients initiated on ART from April 2010 (as this was when 
TDF was commenced in first line ART regimens) to December 2013.  We have selected a convenient 
sample size of 350 patient records. We collected data over a period of 24 months on ART. 
Variables 
The study variables were defined and determined by the nature of the investigation which was guided 
by the scoping review.  They included the following: 
 Demographic data:  name, age, gender, ethnic group 
 Medical history:  history of diabetes, hypertension, tuberculosis, pregnancy. 
 Medication history:  ART regimen 
 Clinical data: weight, height, body mass index (BMI), BP, urine dipstick (was evaluated in 
patients who had the test done), fingerprick glucose. 
 Laboratory data:  CD4, HIV viral load, full blood count, urea and electrolytes, glomerular 
filtration rate, plasma glucose, hepatitis B and C, cholesterol and triglycerides. 
Variables were collected at baseline and thereafter at months 6, 12, 18 and 24 on ART. 
Data Analysis 
Data was analyzed during the research timeline. Analysis was rigorous, consistent and structured in a 
way which that matched the standards for quality assurance. Data was entered in the Excel database at 
the UKZN office in Durban, and was cleaned until there were no longer any discrepancies. 
Descriptive statistics which included frequency distribution, percentages and percentiles, means and 
standard deviations and cross-tabulations were used to describe the characteristics of HIV-related 
renal manifestation at King Edward VIII Hospital ART clinic. 
 
1.7.3. Ethical Considerations 
Risk to participants 
This study consists of a scoping review and a retrospective chart review. Therefore, it did not pose 
any physical, biological or emotional risk to participants.  
Benefits 
To identify gaps in research and to generate a hypothesis for a prospective study. 





We have not disclosed patient identification details. 
Consent 
None needed as there was no interaction with patients. 
Permissions 
 King Edward Hospital, Family Clinic, Department of Internal Medicine 
 Biomedical Research and Ethics Committee (BREC), reference number BE486/15 and 
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CHAPTER 2: A SYSTEMATIC SCOPING REVIEW 
 
Chapter 1 presented the background, aim, objectives and significance, as well as the literature review 
and methodology followed in this study.  The literature review provided an overview of HIV, ART 
and HIV-related renal disease in South Africa.   In order to get a closer look at the literature on the 
renal manifestations of HIV in South Africa during the ARV era, a systematic scoping review was 
conducted.  
This chapter responds to objective 1 of this study viz. to conduct a systematic scoping review to identify 
the literature available on the renal manifestations of HIV infection in the era of ART in South Africa. 
This study was guided by Asksey and O’ Malley’s scoping review framework and revealed gaps in the 
research as well as helping to guide future research on HIV and renal disease in South Africa.  The 
chapter is presented in the form of a manuscript entitled ‘HIV Renal Manifestations during the 
Antiretroviral Era in South Africa: A Systematic Scoping Review’.  This manuscript is currently under 
review at the BMC: Systematic Reviews Journal.   
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Background: It is estimated that 650 000 patients may develop human immunodeficiency virus 
(HIV) related renal disease in South Africa. South Africa has recently adopted the World Health 
Organisation (WHO) policy, stipulating that all HIV-infected patients have access to antiretroviral 
treatment (ART) irrespective of CD4 cell count. The aim of this study is to explore the evidence 
of renal manifestations of HIV in South Africa in the era of ART. 
 
Methods: We searched Google Scholar, PubMed, Medline, Cochrane Library, Worldcat.org and 
EBSCO host databases for articles pertaining to renal manifestations of HIV infection in South 
Africa. We independently reviewed the articles for quality. Thematic content analysis was 
performed to identify patterns of renal manifestations from the included studies. The risk of bias 
(e.g. internal validity) in the included studies was evaluated using the mixed methods appraisal 
tool.   
 
Results: Eleven out of 21 studies were eligible for data extraction. The incidence of urine 
abnormalities on urine dipsticks was high but had poor sensitivity and specificity for detecting 
renal impairment. Normal renal function occurred in 28.4% to 79% of patients, mild renal 
impairment occurred in 19% to 57.1% and moderate renal impairment in 2% to 14.4%. Severe 
renal impairment occurred in 1.3% of patients. Both the Cockcroft-Gault equation (after correcting 
for bias) and the 4-variable Modification of Diet in Renal Disease equation (without the ethnicity 
factor for African Americans) have been validated for the estimation of glomerular filtration rate 
(eGFR) in Black South Africans. HIV-associated nephropathy was the most prevalent histology 
seen (57.2%). Older age, a lower CD4 count, a low haemoglobin and a detectable HIV viral load 
were associated with renal impairment. Renal function improved in the first year of commencing 
ART as evidenced by the regression of proteinuria and the increase in eGFR. 
 
Conclusion: Evidence show that more patients on ART will probably result in a further increase 
in chronic disease in South Africa, mainly chronic kidney disease (CKD), hypertension and 
diabetes. The findings of the review have implications for the recently adopted ‘test and treat’ 
approach to HIV prevention and management. 
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Background 
South Africa recently (01 September 2016) adopted the World Health Organization(WHO) “test 
and treat” approach, which was introduced as a possible means of controlling the global HIV 
epidemic (3). This approach entitles every patient who tests positive for HIV to a lifelong 
antiretroviral therapy (ART) regardless of their CD4 count or clinical staging (3). With the 
successful rollout of ART in South Africa, the lifespan of people living with human 
immunodeficiency virus (HIV) has been prolonged thereby transforming HIV into a disease of 
chronicity (1), adding to the burden of infectious and non-communicable diseases (2). Renal 
disease is a recognised complication of HIV infection and its incidence can be perpetuated by drug 
induced toxicity, comorbid diseases such as diabetes and hypertension and infectious diseases (3). 
Data from the United States suggest that at some stage of their HIV infection, 10% of patients will 
develop HIV-related renal disease (4). If this is extrapolated to the South African context, it is 
estimated that 650 000 patients may develop HIV-related renal disease (4). This large burden of 
chronic kidney disease (CKD) would place immense pressure on our resource-strained health 
system where access to renal biopsy, renal replacement therapies and nephrologists is limited (5). 
 
Mayosi et al. report a 67% increase in deaths related to nephritis/nephrosis in South Africa from 
1999 to 2006 causally linked to the increasing HIV prevalence (2). In their systematic analysis, 
Stanifer et al. found that CKD is a prevalent and potentially growing disease in Sub-Saharan Africa 
with 24% of hypertensives, 18.9% of diabetics and 10% of HIV-infected patients having co-
morbid CKD (6). The guidelines published by the Infectious Diseases Society of America (IDSA) 
in 2005, recommended that all individuals be assessed for kidney disease at the time of HIV 
diagnosis by way of a screening urinalysis for proteinuria and a calculated estimate of renal 
function (7) in order to detect renal disease early. The South African ART guidelines incorporate 
this policy and the recent implementation of ART initiation irrespective of CD4 count allows for 
earlier access to ART before the onset of advanced disease (3).  
 
Despite the earlier initiation of ART and the screening for urinary abnormalities, renal disease in 





has become the third leading cause of end stage renal disease amongst HIV infected African-
American patients (9, 10). To the best of our knowledge, this is the first systematic scoping review 
that attempts to investigate the renal manifestations of HIV infected in South Africa in the ART 
era. In light of the current upsurge of research and publications on the topic (9, 11-14), the 
contribution of a systematic scoping review gains importance and relevance by demonstrating the 




The protocol of this study is registered in PROSPERO with registration number: 
CRD42016039270 and available via this website: 
 http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016039270.  
 
In this study, we chose to undertake a systematic scoping review of published reviews as the best 
method to map the renal manifestations of HIV in South Africa in the era of ART. Guided by 
Arksey and O’Malley’s scoping review framework (15), we searched cross-sectional studies, 
randomised controlled trials, non-randomised controlled trials, observational studies, review 
articles, case reports and systematic reviews that examined renal manifestations on HIV-infected 
patients in South Africa.  
 
Literature search  
We conducted a systematic literature search in the following databases: Google Scholar, PubMed, 
Medline, Cochrane Library, Worldcat.org and EBSCO host, for articles pertaining to renal 
manifestations of HIV in South Africa. The primary search terms related to HIV and the kidney 
specifically (i.e. kidney, renal, nephrology). The secondary terms were manifestations, renal 
failure, complications, South Africa, antiretroviral treatment, proteinuria and glomerular filtration 
rate. In order to direct the search to our research question, we used the filtering method which 
included the data range (2004 to 2015), human subjects, English language and adult patients (≥18 
years old). Medical subject headings (MeSH) terms were also used.   
 






 Evidence of renal manifestations in HIV infected patients in South Africa  
 Evidence from the period 2004 to 2015 
 Evidence of renal manifestations in adult HIV infected patients (≥18 years old) 
 English language publications 
 
Exclusion criteria 
 Evidence of renal manifestations in HIV infected patients outside South Africa  
 Studies reporting on other HIV manifestations 
 Studies before freely available ART in the public sector of South Africa 
 Non-English language studies 
 
Study selection occurred in two stages. First a single reviewer went through the titles from the 
database search and decided on eligibility based on the inclusion and exclusion criteria. For 
example, titles stating research carried out in an ineligible country would be excluded. If a reviewer 
was uncertain of the eligibility of a title, it was not excluded but rather carried onto the next stage 
of the selection process. In the second stage, two independent reviews of the titles and abstracts, 
using inclusion and exclusion criteria, was undertaken. Where differences of opinion arose, a third 
reviewer would be consulted to reach consensus. The remaining articles were then assessed for 
eligibility for data extraction. A PRISMA flow diagram (Figure 1) shows the process involved in 
obtaining eligible studies.  
 
Quality of the evidence 
The risk of bias (e.g. internal validity) in the included studies was evaluated using the mixed 
methods appraisal tool (MMAT) for mixed methods studies (16). The risk of bias scale scored 
studies was based on 14 criteria. Studies were assessed by the following domains: 
representativeness of population; selection of exposed and non‐exposed cohorts drawn from the 
same population; confidence in the assessment of exposure; confidence that the outcome of interest 
was not present at the start of the study; matching exposed and unexposed variables for all those 
that are associated with the outcome of interest or the adjustment of statistical analysis for these 





confidence in the assessment of outcome; adequacy of the follow up of cohorts; and the adequacy 
and similarity between groups of co‐interventions. Studies were allocated scores per domain. Two 
reviewers (SA and SMK) independently performed each quality assessment. Differences in ratings 
were resolved through discussion. 
Thematic analysis 
Thematic content analysis was performed to identify patterns of renal manifestations from the 
included studies. The included manuscripts were manually coded into categories which were 
grouped into the following five themes: 
 Urine analysis 
 Estimated glomerular filtration rate 
 Renal biopsy 
 Risk factors for renal dysfunction 
 Clinical and histological responses to ART 
 
Results 
A total of 6 808 articles were retained from our initial search. Applying our exclusion criteria 
reduced the number of studies to 11 (Figure 2.1). The level of agreement between reviewers was 
80% versus 50% expected by chance. This constitutes moderate to substantial agreement, with 









































Figure 2.  1: Literature search and selection of studies 
 
Characteristics of included studies 
Eleven out of the 21 reviewed articles were eligible for data extraction (Table 2.1). All 11 studies 
were published in English and they were conducted in South Africa. Of these, eight were 
conducted in an urban setting (12, 13, 17-22) and three were carried out in a rural setting (23-25). 
Records identified through 
database searching 






























 Additional records identified 
through other sources 
(n = 0) 
Records after duplicates removed 
(n = 6 789) 
Records included after 
screening 
(n = 172) 
Records excluded after 
screening 
(n = 6 597) 
Full-text articles assessed 
for eligibility 
(n = 21) 
Full-text articles excluded, 
with reasons (n =  59) 
 
1. Study not in South Africa 
(n = 49) 
2. Not within time frame (n 
=  6) 
3. No evidence of renal 
disease (n = 1) 
4. Article in a dissertation 
(n = 1) 
4. Systematic review/meta-
analysis (n = 1) 
5. Irrelevant study 
population (n = 1) 




Studies included in 
qualitative synthesis 





All included studies were published between 2008 and 2015. Study participants were 
predominantly female (total female percentage 57.9%) in all included studies except two (19, 20). 
The total sample size of all 11 studies was 6 595 participants. The sample size in each study was 
100 participants or more. The average age in all the included studies was 35 years. The study 
designs of the included studies were as follows: four retrospective chart/cohort reviews (17, 19, 
21, 22); one cohort study (26); one descriptive study (13);  two prospective studies (12, 20); one 
combined retrospective chart review and prospective cohort study (23); one case control study 
(18); and one cross-sectional analysis of patient records (27).  
 
All the included studies were aimed at assessing the renal status, risk factors and renal outcomes 
in HIV-infected patients either before ART, whilst on ART or both. Seven of the 11 studies 
(63.6%) assessed for the prevalence of renal impairment in HIV-infected patients (13, 17, 19, 22, 
23, 26, 27); two studies (18.1%) analysed renal biopsies to evaluate the clinical and histological 
responses of HIV-associated kidney disease to ART (12, 21); one study (9%) assessed the 
performance of the 4-variable Modification of Diet in Renal Disease (4-v MDRD) and Cockcroft-
Gault (CG) equations for estimating glomerular filtration rate (eGFR)/creatinine clearance in 
South African Black patients (20); and one study (9%) extracted genomic DNA from kidney 
samples to determine the prevalence of APOL1 risk variants and their effect on CKD in Black 
South Africans (18). General and specific characteristics of all included studies are summarised in 
Table 2.1.  From Table 2.1 we extracted data specific to the evidence of renal dysfunction among 
HIV infected patients in South Africa during the ARV era and formulated Table 2.2. 
 
A total of 6 758 studies were excluded as they did not meet the inclusion criteria for this study.  Of 
those, 10 underwent a full manuscript review and were found to have no valuable data for analysis 
in this study for the following reasons: not within the specified time frame (9, 14, 28-31); outcomes 
of chronic haemodialysis (32); systematic review and meta-analyses of countries in Sub-Saharan 





Table 2. 1: Characteristics of included studies 
AHR = adjusted hazards ratio; AIDS = Aquired Immunodeficiency Syndrome; AKI = acute kidney injury; aOR = adjusted odds ratio; ART = antiretroviral 
















Outcome Aim of the 
study 

























Of 890 patients 
initiated on tenofovir, 
573 (64.4%) had 
normal renal function 
(>90ml/min), 271 
(30.4%) had mild 
renal dysfunction 
(60–89ml/min) and 46 





died and 9.7% were 
lost during 48-months 
of follow-up. Patients 
with mild or moderate  
renal dysfunction 
were at greatest risk 
of nephrotoxicty, 




























filtration rate; HIV = human immunodeficiency virus; HIVAN = human immunodeficiency virus associated nephropathy; HIV-ICD = human immunodeficiency 
virus immune complex disease; HR = hazards ratio; IQR = inter-quartile range; MDRD – Modification of Diet in Renal Disease; OR = odds ratio; SD = standard 
deviation; STI = sexually transmitted infection; TB = tuberculosis; TDF = tenofovir disoproxal fumarate; WHO = World Health Organization
or moderate renal 
dysfunction vs. 
normal renal function 
were at highest risk of 
death by 48-months. 
Fabian et 
al., 2009 







None 84% of the screened 
population had AIDS 
(CD4 count, 200 




testing was high: 30% 
had leukocyturia, 
33% had microscopic 
hematuria, and 44% 
had 
microalbuminuria/pro
teinuria. In patients 
with leukocyturia, an 
infective organism 
was cultured in only 
29.1% of cases, 
predominantly 
Escherichia coli 







































Urban 20 renal 
biopsies 
performe




























There was a rapid 
immunological and 
renal response to 
ART. The renal 
response was 
reflected by a 
significant rise in the 
estimated glomerular 
filtration rate (eGFR) 
and rapid regression 
of proteinuria. The 
histological patterns 
were highly variable, 
ranging from non-
specific lesions such 
as mesangial 
hyperplasia and 
interstitial nephritis to 
HIV-immune 
complex disease 
(HIV-ICD) with or 
without features of 
HIV-associated 
nephropathy 









































response to treatment 
was variable with a 
combination of no 
change, progression 













31.2% 68.8% 36 1.Retrospecti















None 1. Moderate renal 
impairment was more 
frequent (287/2189), 









2.Urine analysis had 




















































































Majority had normal 
renal function pre-
ART (79%), 19% had 
mildly reduced eGFR, 
and 2% had moderate 
renal impairment. 
Older age, more 
advanced WHO stage 







improved over the 
first year on tenofovir. 
Male gender, anaemia 
and 
immunosuppression 
(WHO Stage III/IV 
and CD4 cell counts 
<100 cells/mm3) 
were associated with 
lower average eGFR 
levels over time. 
Overall, 3% 
developed eGFR <50 
ml/min/1.73 m2 



















































Serum creatinine tests 
conducted before 4 
months on ART had 
low predictive value 
for predicting change 





li et al., 
2015 


















































a modified in 
house salting-
out procedure 





























79% of patients with 
HIV-associated 
nephropathy and 2% 
of population controls 
carried two risk 
alleles. In a recessive 
model, individuals 
carrying any 
combination of two 
APOL1 risk alleles 
had 89-fold higher 







7.3% for G1 and 
11.1% for G2. 
APOL1 risk alleles 






























are at very 













associated with other 




Rural 302 45.4 54.6 47.1 Reviewed 
records, kept 
at the CKD 






None 290 (96%) were black 
African. Mean age ± 
SD was 47.1 ± 17.0 
years. Approximately 
86.4% of females and 
54.5% of males were 
overweight/ obese. 
Dyslipidaemia was 
observed in 47.9% 
females and 29.2% 
males (P < 0.001). 
Estimated glomerular 
filtration rate (eGFR) 
was <30 ml/min/1.73 
m2 in 50.6% patients. 























































































Ninety-nine (98%) of 
HIV-positive patients 
were black and 56 
(55%) were male, 
with mean age 38 ± 





with mean CD4 count 
of 135 cells/μL Fifty-
seven (56%) HIV 
positive patients 
presented with AKI, 
21 (21%) with acute-
on-chronic kidney 
disease and 23 (23%) 
with CKD; seven 
patients with AKI 
were excluded due to 
lack of records. The 








































with AKI at a 
younger age 


























Forty-four per cent of 
HIV positive and 47% 
of HIV-negative 
patients with AKI 
demised; P=0.45. 






predictors of mortality 
in HIV-positive 











Urban 100 51% 49% 47 Measurement 















and estimated GFR 
for both equations 
was similar. Using the 
4 vMDRDequation 



























factor of 1.212 as 
established for 
African Americans 
resulted in a median 
positive bias of 13.1 
(95% CI 5.5 to 18.3) 
mL/min/1.73m2.With
out the ethnicity 
factor, median bias 









GFR and to 
assess the 
appropriate

















bias, can be 
used for 
estimating 
















(HIVAN) was the 
most common 
histology. ART 
reduced the mortality 
in those with any 





























57%.  Of those 
patients with HIVAN 
who died, 79% died 
of renal failure as 




shown to be poor 
prognostic indicators 
In patients with 
HIVAN alone 
followed for up to 2 
years on ART, 
estimated glomerular 
filtration rate 
remained stable and 
there was a trend 
towards decreased 
proteinuria. ART 
improved survival in 































































had been on 
ART for at 
least six 
months 
The median duration 
since HIV diagnosis 
was 26 months and 
787 (87%) received 
antiretroviral therapy. 
Thirty-six (4%) of the 
subjects were shown 
to have diabetes and 
205 (23%) 
hypertension. In the 
cohort, 21% had 
albuminuria and 2% 





cholesterol, eGFR and 




























































might be the 
















circle of renal 
failure and 
cardiovascula











Table 2.2. Evidence of renal dysfunction among HIV infected patients in South Africa during the 
ARV era 
 
AUTHOR MARKERS FOR 
RENAL 
IMPAIRMENT 
DEFINITION OF RENAL 
DISEASE 
RESULTS 





Nephrotoxicity defined as 
any decline in kidney 
function from baseline (acute 
or chronic) that is secondary 
to a toxin (including drugs) 
documented within 48 
months of initiating tenofovir 
(TDF).  
Normal renal function 
(>90ml/min), mild renal 
dysfunction (60-89ml/min) 
and moderate renal 
dysfunction (30-59ml/min) 
The risk of nephrotoxicity and 
death by 48 months increased 
with decreasing renal function at 
initiation of TDF.  Patients 
switched onto TDF had a higher 
risk of nephrotoxicity and death 
compared to ART naïve patients. 
Median time to nephrotoxicity 
after TDF initiation is 3.6 months 
confirming the importance of the 
month 3 creatinine clearance. 
Fabian et al, 
2009(13) 






independent of sex; 
Overt proteinuria: protein-to-
creatinine ratio of 0.03-
0.3g/mmol; 
Nephritic range proteinuria: 
protein-to-creatinine ratio 
>0.3g/mmol. 
18.5% had microalbuminuria, 
6.4% had overt proteinuria and 
2.4% had nephrotic range 
proteinuria. 
Fabian et al 
2013(12) 
Urine dipstick for 
proteinuria. 
Estimated glomerular 
filtration rate (eGFR) 
using both CG and 4 
variable Modification 






ratio of 3.4-33.9mg/mmol; 
Persistent overt proteinuria: 






68% had microalbuminuria, 23% 
had overt proteinuria and 9% had 
nephrotic proteinuria. 
There was an improvement in 
eGFR on antiretroviral treatment 
(ART). There was partial or 
complete remission of proteinuria 
in response to treatment.  Despite 
the rapid clinical response to 
ART, there was relative lack of 
histological resolution. 
Franey et al, 
2009(23) 
Urine dipstick for 
proteinuria. 
eGFR using the four 
variable MDRD 
equation. 
Urine dipstick for 
proteinuria 
 
Severe renal impairment: 
eGFR <30mls/min/1.73m2; 
Moderate renal impairment: 
eGFR 30-60mls/min/1.732; 
Mild renal impairment: eGFR 
60-90mls/min/1.732. 
Proteinuria ≥ 1+ protein on 
dipstick. 
Renal dysfunction defined as 
either reduced eGFR and/or 
proteinuria/haematuria. 
Severe renal impairment was 
uncommon while moderate and 
mild renal impairment were more 
common.  Mild and moderate 
renal impairment improve on 
ART.  Urine analysis may not be 
sufficiently sensitive to be used as 
a single screening test for renal 
disease at baseline. 
Kamkuemah et 
al, 2015(35) 
eGFR calculated using 
CG equation 
Severe renal function 
reduction was defined as 
79% had normal renal function at 
baseline, 19% had mildly reduced 





eGFR <30 ml/min/1.73 m2, 
moderate reduction 
as eGFR of 30–59 
ml/min/1.73 m2 and mild 
reduction as an eGFR of 60–
89 ml/min/1.73 m2. 
moderate renal impairment at 
basleine. Overall renal function 
improved over the first year after 
starting TDF-containing ART 
regimens.   
Madala et al, 
2014(24) 
Urine dipstick for 
proteinuria. 
eGFR calculated using 
the MDRD equation 
for ≥ 18 years and the 
Schwartz equation for 
< 18 years old. 
Chronic kidney disease 
(CKD) defined by eGFR < 
60ml/min/1.73m2 and/or 
proteinuria and/or abnormal 
renal ultrasound, persistent 
for ≥ 3 months. 
eGFR was < 30ml/min/1.73m2 in 
50.6% of patients as this was a 
CKD clinic.  Main risk factors for 
CKD were diabetes, hypertension 
and HIV. 
Vachiat et al, 
2013(19) 
Urine for proteinuria 





Acute kidney injury (AKI) 
defined as an improvement in 
admission serum creatinine of 
> 50%.  They were further 
subdivided using the rifle 
criteria: Risk – serum 
creatinine < 194µmol/L; 
Injury – serum creatinine 195 
to 291µmol/L; and Failure – 
serum creatinine > 
291µmol/L. 
Majority had AKI 56%, followed 
by CKD 23% and 21% had acute 
on chronic kidney disease.  
Proteinuria did not predict 
recovery or death in HIV-infected 
patients with AKI.  AKI was 
common in HIV-infected patients 
and occurred at a younger age 
than HIV negative patients. 







(HIVAN) defined as a 
constellation of glomerular, 
interstitial and tubular 
abnormalities and there must 
be epithelial cell hyperplasia 
if only tubular or interstitial 
disease was present. 
For patients with HIVAN there 
was an improvement in 
proteinuria and stabilization of 
renal function after commencing 
ART.  Renal biopsy is essential to 
diagnose renal disease in HIV-
infected patients. 
Wensink et al, 
2015(25) 
Urine for albuminuria 
eGFR calculated using 





creatinine ratio 30 to 
299mg/g;   
Severely increased 
albuminuria: albumin 
creatinine ratio > 300mg/g. 
 
Albuminuria occurred in 20% of 
patients while only 2% had eGFR 
< 60ml/min/1.73m2.  Higher 
eGFR was significantly linked to 
lower prevalence of albuminuria.  
Albuminuria was linked to higher 
frequency of diabetes, 
hypertension, high total 
cholesterol and decreased eGFR.   
 
 
Risk of bias assessment  
The studies’ quality scores ranged from 16 to 20 out of a maximum score of 28 (Appendix D). 
Four of the ten included studies scored the highest quality score with an estimated average score 
of 10 in each study (13, 21, 23, 25). The two studies scoring the lowest had an average score of 8 





following: description of randomisation; allocation concealment; retention percentage in study; 
minimising selection bias; and selection and comparativeness of the control groups. 
 
Findings of the study 
Kidney disease is a complication of HIV infection and can present as acute kidney injury (AKI) or 
CKD.  Only one study assessed AKI in HIV-infected ARV naïve patients (19).  Their findings 
demonstrated that 56% had AKI, 21% had acute or chronic kidney disease and 23% had CKD 
(19). The causes of AKI included sepsis, volume depletion, haemodynamic instability, toxins, 
urological obstruction and miscellaneous causes (19). 
  
We identified patterns of renal manifestations from the included studies and grouped them into the 
following five themes: urine analysis; estimated glomerular filtration rate; renal biopsy; risk 
factors for renal dysfunction; and clinical and histological responses to ART. 
 
Urine analysis 
The incidence of urine abnormalities on urine dipsticks was high: 30% to 57% had leukocyturia 
(13, 19), 16% to 40%  had microscopic haematuria (13, 19, 23) and 20% to 44% had 
microalbuminuria/proteinuria (12, 13, 23, 26). Two studies investigated the cause of leukocyturia 
and detected an infective organism, mainly E.Coli, in 29.1% of culture positive cases in one study 
(ART naïve outpatients) (13) and in 8.9% of culture positive cases in the other study (ART naïve 
outpatients with renal failure) (19). Franey et al. performed urine dipstick analysis on 149 patients 
who were initiating ART in a rural clinic, to assess its utility to detect impaired renal function (23). 
They concluded that urine dipsticks analysis alone had poor sensitivity and specificity for detecting 
impaired renal function (PPV 0.22) (23).   
 
In three studies on ART naïve patients, positive proteinuria on dipsticks was quantified by sending 
the specimen for a spot protein:creatinine ratio (PCR) (12, 13, 19). If the dipsticks were negative 
for protein they were screened for microalbuminuria which, if positive, were then sent for a spot 
microalbumin-to-creatinine ratio test (MCR) (12, 13). In their study, Fabian et al. found that, of 
the 253 dipsticks positive for proteinuria on ART naïve patients, only 193 were confirmed by the 





albumin:creatinine ratio (ACR), bypassing urine dipsticks analysis. Two studies quantified the 
degree of proteinuria using either the MCR (12) or the ACR (26). Microalbuminuria (MCR 3.4-
33.9 mg/mmol) occurred in 68% of patients, overt proteinuria (MCR 34 mg/mmol-0.3 g/mmol) in 
23% and nephrotic proteinuria (MCR >0.3 g/mmol) in 9% of ART naïve patients (12). Similar 
figures were noted in the study that quantified the ACR in a mixed study population predominantly 
on ART (87% on ART):  20% of patients had moderately increased albuminuria (ACR 30–299 
mg/g) and 1% had severely increased albuminuria (ACR >300 mg/g) (26). In the same study, a 
detectable HIV viral load, hypertension, total cholesterol and eGFR were all independently 
associated with albuminuria (26).   
 
Estimated Glomerular Filtration Rate (eGFR) 
Six studies utilised eGFR as a marker of renal dysfunction (12, 17, 20, 22, 23, 26). eGFR was 
calculated using the CG equation (17, 22), the 4-v MDRD equation (23), comparing the CG and 
4-v MDRD equations (12, 20) or comparing the 2009 Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) formula and the 4-v MDRD equation (26).  Both the CG equation (after 
correcting for bias) and the 4-v MDRD equation (without the ethnicity factor for African 
Americans), have been validated for the estimation of eGFR in Black South Africans (20).   
 
The eGFR was classified as follows: severe renal impairment eGFR <30mls/min/1.73 m2, 
moderate renal impairment eGFR 30–59mls/min/1.73 m2, mild renal impairment eGFR 60–
89mls/min/1.73 m2 and normal renal function eGFR >90mls/min/1.73 m2. Using the afore-
mentioned classification, baseline (before ART initiation) renal function was documented as 
follows: normal renal function occurred in 28.4% to 79% of patients, mild renal impairment 
occurred in 19% to 57.1% and moderate renal impairment in 2% to 14.4% (17, 22, 23).  Baseline 
severe renal impairment occurred in 1.3% of  ART naïve patients in the study by Franey et al. (23). 
Wensink et al. had a mixed study population of ART naïve patients and HIV-infected patients on 
ART and the majority of patients had normal renal function, 2% had moderate renal impairment 
and 10% had mild renal impairment (26).   
 
Brennan et al. confirmed the importance of the 3 month creatinine clearance by demonstrating that 





months (17). A study by Kamkuemah et al. showed that early serum creatinine testing at months 




Renal histological findings have been inconsistently classified in patients on ART (21). HIV-
associated nephropathy (HIVAN) was the most prevalent histology seen (57.2%) followed by 
HIVAN with immune complex glomerulonephritis (ICGN) at 21.8%; without HIVAN or ICGN 
(12.5%); and ICGN in isolation (8.3%) (21).  However, in another study by Fabian et al., there 
was a paucity of HIVAN lesions on histology (12).   
 
Risk factors for renal dysfunction 
Two studies were unanimous that abnormal renal function at baseline was associated with older 
age, World Health Organisation (WHO) stage III/IV disease and a lower CD4 count (22, 23, 35). 
In addition to these variables, a low haemoglobin and a detectable HIV viral load were also 
associated with abnormal renal function in a mixed cohort of ART naïve patients and patients on 
ART (17, 22). In the same study, patients who were switched onto TDF from another regimen had 
a higher risk of nephrotoxicity and death, than ART naïve patients initiated on TDF (17). Younger 
age and advanced immunosuppression were found to be risk factors for AKI (19).  There was no 
consensus regarding gender as a risk factor for renal dysfunction, as one study found women to be 
at greater risk (22) whilst another found men to be at greater risk (23).  The APOL1 risk allele 
found on chromosome 22 occurred in more than 30% of African American individuals with 
HIVAN (36). Kasembeli et al. showed that 79% of Black patients with HIVAN carried two copies 
of APOL1 risk alleles as opposed to 2% in the general population, suggesting that ART naïve 
Black South Africans were at high risk of developing HIVAN(18).  CKD (defined as eGFR < 
60ml/min/1.73m2 and/or proteinuria and/or abnormal renal ultrasound persistent for ≥ 3 months) 
risk factors which were noted in two studies of South African patients attending CKD clinics, 
were: hypertension (36% to 77.8%), diabetes (25% to 29.8%) and HIV (20% to 28.5%) (20, 27).  
It is interesting to note that 51.1% of these patients had more than one CKD risk factor (27). 
 





In the majority of patients, renal function improved in the first year of commencing ART, as 
evidenced by the regression of proteinuria and the increase in eGFR (12, 21, 22). However, there 
was no significant change in morphology noted on histology before and after ART initiation to 
explain the improvement in proteinuria (12).    
 
Discussion        
A systematic scoping review of the available literature on the renal manifestations of HIV in the 
era of ART in South Africa was conducted. This review provided a general overview of renal 
impairment (diagnostics, histological features and risk factors) in South African HIV-infected 
patients mainly prior to ART initiation. Most of what we know about HIV-related kidney disease 
has come from research performed in high income countries where the patient profiles and 
demographics are discordant to that of South Africa. The salient points unravelled by our review 
indicate a paucity of data on ART-related renal complications, specifically TDF nephrotoxicity; a 
deficiency of research on the impact of ART on AKI and CKD and the long term outcomes of 
renal disease for patients on ART; and a relatively unknown prevalence of HIV-related kidney 
disease for patients on ART in South Africa. Bearing in mind that South Africa recently (1 
September 2016) adopted the WHO “test and treat” approach to HIV prevention and management 
(3), these findings have major implications for the near future.      
 
TDF is widely used as first line ART in South Africa. A biopsy series revealed that TDF 
nephrotoxicity is essentially a reversible form of toxic acute tubular necrosis with features of 
mitochondrial injury (37). Numerous studies have demonstrated a decrease in kidney function with 
TDF usage and suggest monitoring of renal function to prevent TDF nephrotoxicity (17, 38-40). 
Early detection of proteinuria using accurate screening tests is important to decrease 
nephrotoxicity and improve outcomes in HIV-infected individuals (17). The current South African 
ART guidelines recommend routinely performing urine dipstick analysis on patients before and 
while on ART, as well as assessing the serum creatinine and eGFR at baseline (prior to ART 
initiation) and then at 3 months, 6 months, 12 months and annually thereafter for patients on TDF.  






The use of urine dipsticks alone as a screening tool has become a contentious issue with research 
both locally (23) and overseas (41) suggesting the poor validity of urine dipsticks in detecting 
proteinuria. Data from another South African study, Han et al., suggested that HIVAN is possible 
in patients without overt nephrotic syndrome and in patients who have only microalbuminuria. 
Therefore microalbuminuria can be considered an early marker of HIVAN (9). Szczech et al. 
concluded that miroalbuminuria predicts the development of proteinuria in HIV-infected patients 
(42). Stanifer et al. showed that the prevalence of proteinuria when measured in people with HIV, 
hypertension or diabetes is substantial. However the best method of urine protein detection is 
unknown (6). Currently, our urine dipstick analyses detect proteinuria only (not 
microalbuminuria). In other countries, alternate methods of urine analysis are already being 
sought. In a recent study set in Mexico City, a comparison was made between the protein reagent 
strip (PRS) and the urinary protein/creatinine ratio (uPCR) to detect proteinuria. It was concluded 
that there was a high concordance between the detection of urine protein by PRS and uPCR and 
therefore the PRS could be useful in low income countries to detect proteinuria (43).   
 
Two South African studies in our review demonstrated the importance of an early creatinine 
clearance, prior to 4 months after the initiation of TDF (17, 22). Both the CG equation (after 
correcting for bias) and the 4-v MDRD equation (without the ethnicity factor for African 
Americans) have been validated for the estimation of eGFR in Black South Africans (20). The 
production of creatinine is determined mainly by muscle mass and dietary intake (44).  Therefore, 
using the ethnicity factor in the 4-v MDRD equation overestimates the eGFR in Black South 
Africans (20) due to differences in diet, muscle mass and body composition between Black South 
Africans and African Americans (20). In the current review, the majority of the patients had mild 
to moderate renal dysfunction with a low prevalence of severe renal impairment prior to ART 
initiation. Similar findings were seen in a study by Overton et al. set in Washington (45). The 
prevalence of significant renal impairment in a South African study (23) was slightly higher than 
that of a Kenyan study (46), possibly because of the differences in the two African populations 
and because the eGFR method used in the South African study has not been validated for use in 
other African countries. Though the prevalence of chronic renal failure is low in the HIV-infected 
population, it has been shown to be higher than that of the general population in an American study 





presented with proteinuria had HIV-related kidney disease (9) and another study of 99 in-patients 
who underwent renal biopsy showed that 27 patients (27.3%) had HIVAN, only 3 of which were 
on ART (14).   
 
In the current review, HIVAN was the most common histology seen on renal biopsy (12, 21).  
Other histologies have been documented in various studies both locally (9, 14, 21, 30) and overseas 
(47). The third leading cause of end stage renal disease (ESRD) in African Americans aged 
between 20 to 64 years was found to be HIVAN (10). HIVAN is commonly found in HIV-infected 
Black patients, suggesting a role of genetics in the development of HIVAN (10).  Kasembelli et 
al. proved that Black South Africans who carried two copies of the APOL1 risk alleles were at 
higher risk of developing HIVAN (18). Lucas et al. demonstrated that ART can prevent or reduce 
the risk of developing HIVAN and, should it occur, patients on ART may have a slower course 
and lower mortality than patients not on ART (48). Following the diagnosis of HIVAN, patients 
can progress to end stage renal failure within months (14). In a South African study over a 10 year 
period of renal biopsies, the incidence of HIVAN increased from 6.6% in 2000 to 25.7% in 2009 
(30). Furthermore, of the 27 patients diagnosed with HIVAN on renal biopsy in a study in South 
Africa, only 3 were on ART (14). This reaffirms the importance of renal biopsy in accurately 
diagnosing renal disease, particularly HIVAN (9, 14, 47), and that ART can be initiated early to 
improve outcomes. Sadly, due to a lack of resources and specialists, access to renal biopsy is 
limited to urban tertiary hospitals in South Africa.  
 
From September 2016, when ART was to have been made universally available to all HIV-infected 
South Africans in accordance with WHO ART guidelines (3), even patients with undiagnosed 
HIVAN would have been initiated on ART. We know from studies in other countries that renal 
function improves with ART. In a randomised ART trial in Uganda and Zimbabwe, there was 
stabilisation or a slight improvement in renal function after the initiation of ART (49). Another 
study demonstrated the resolution of renal disease with ART and the recurrence of renal disease 
after stopping ART (50). TDF-induced renal toxicity usually resolves after TDF cessation, but the 
TDF related renal damage is not always completely reversible (51). Our systematic scoping review 
demonstrated that renal function essentially improved on ART (12, 21, 22). However, data on the 





was noted that 2015 had the most publications applicable to the topic of our scoping review, 
indicating a recent increase in interest on this subject in South Africa. 
 
Recommendations for future research 
The majority of the included studies were conducted in an urban setting where access to healthcare 
and laboratories was readily available. However, research shows high HIV prevalence and fewer 
patients on ART, in rural South Africa (52). Females bear the brunt of the HIV epidemic in South 
Africa having a significantly higher prevalence of HIV than their male counterparts (52). In the 
current review, consensus was not reached regarding gender as a risk factor for renal dysfunction 
possibly because females predominated in most studies. Therefore, comparative studies to 
determine the differences in renal manifestations between HIV infected males and females, 
preferably in rural settings, during the ART era, are recommended. More males need to be recruited 
to participate in research.   
 
Currently, our urine dipstick analyses, detect only proteinuria, and not microalbuminuria.  This 
suggests a novel idea for research: looking at the significance of microalbuminuria versus 
proteinuria in our HIV-infected population, the outcome of which could guide future urine 
diagnostics in baseline screening for renal disease. Cost effective methods for urine screening and 
estimating GFR are needed, especially for rural areas where access to laboratories is limited. 
 
Considering that the majority of South African HIV-infected patients are Black and with a genetic 
predisposition to HIVAN, we anticipate that the prevalence of undiagnosed HIVAN will be 
significant. As far as we know, there are no prospective randomised controlled trials in South 
Africa investigating treatment options for HIVAN and no data on the actual prevalence of HIVAN.   
 
Data on TDF nephrotoxicity and its impact on long term renal function are lacking in South Africa.  
Prospective clinical trials focussing on TDF nephrotoxicity and its long term renal outcomes are 
needed.  
 
The overall prevalence of renal disease in South Africa is unknown. We urgently need 





South Africa in order to efficiently plan and sustain an effective CKD programme. The 
establishment of renal registries will assist with much needed statistics on the morbidity and 
mortality of renal disease in general and specifically to HIV and ART.   
 
Implications for practice 
Risk factors associated with proteinuria and albuminuria in HIV-infected patients (low eGFR, 
older age, diabetes and HPT) (25, 53) overlap with those for CKD patients (27, 54). Stanifer et al. 
found that 24% of hypertensives, 18.9% of diabetics and 10% of HIV-infected patients have co-
morbid CKD in Sub-Saharan Africa (6). With the high burden of HIV and non-communicable 
diseases such as CKD, hypertension and diabetes in South Africa, it would be wise for the Health 
Department to invest in CKD clinics in rural areas and nephrology outreach services as previously 
proposed by Madala et al. (27). All staff must be trained in screening for renal dysfunction and 
referral pathways and support systems must be in place for patients to access specialist care. In 
South Africa, the number of nephrologists per million population is estimated to be 1.1 (55). The 
lack of specialists must be addressed in order to have optimally functioning and widely accessible 
CKD facilities, as well as access to renal biopsy and renal replacement services. We must build on 
our current infrastructure.   
 
Lastly, we need to empower our patients with knowledge regarding ART complications, and the 
monitoring and recognition of side effects. In over-burdened health facilities, it is not unusual for 
important management steps to be overlooked. Therefore, if we educate our patients, these can be 
avoided. 
 
Strengths and Limitations 
An important strength of this study is the exhaustive search for relevant studies. Scoping review 
methodology is rigorous and methodical in its approach to examining the extent, range and nature 
of research activity in a particular field (15).  There are no limitations in this study. 
 
Conclusion 
The findings of the review are in keeping with that of international literature. South Africa has 





to ART irrespective of CD4 cell count. Though this is a victory for the millions still awaiting ART 
in South Africa (in this context particularly patients with undiagnosed HIVAN), the impact on the 
current health infrastructure that this strategy will have, is unknown. More patients on ART may 
result in a further increase in chronic disease in South Africa, mainly CKD, hypertension and 
diabetes.  Early initiation of ART can prevent HIVAN and improve outcomes for patients with 
HIVAN thereby potentially decreasing the incidence of CKD.  With a lack of dedicated CKD 
clinics and specialist renal services particularly in the rural settings, as well as a deficiency in 
knowledge on the long term impact of ART on CKD, this may be a victory for which the healthcare 
system could be ill-prepared. 
   
More research is urgently needed on the impact of ART on renal disease, ART-related renal 
complications and the prevalence of CKD, as well as cost effective methods for routine screening 
of renal disease in resource-poor settings 
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CHAPTER 3: A CHART REVIEW 
 
Chapter 2 demonstrated the current stance on HIV-related renal disease in South Africa.  It 
revealed research gaps in this area.  With the universal access to ART for all HIV-infected 
South Africans, the burden of renal disease and other chronic diseases is anticipated to increase.  
Therefore, more research on the long term effects of ART on renal disease and on the morbidity 
and mortality of renal disease, is required.   There are guidelines in place regarding monitoring 
of patients on ART but it is not known whether these guidelines are being adhered to. Guided 
by the results obtained in Chapter 2, a chart review was conducted in an HIV-infected cohort 
from the clinic medical records. 
Chapter 3 presents a retrospective chart review aimed at addressing objective 2 of the study 
viz. to determine the risk factors and co-morbidities associated with renal impairment in a 
cohort of HIV-infected patients.  The results of this will help to influence policy and guide 
future research on HIV management. The chapter is presented in the form of a manuscript 
entitled: ‘Risk Factors and Co-Morbidities Associated with Changes in Renal Function among 
ART-naïve Adults in South Africa: A Chart Review’. The manuscript is currently under review 
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Introduction : Our systematic scoping review has demonstrated a research gap on 
antiretroviral treatment (ART) nephrotoxicity, as well as the long term outcomes of renal 
function for patients on ART in South Africa.  Bearing in mind the high prevalence of human 
immunodeficiency virus (HIV) in South Africa, this is of great concern. The aim of this study 
is to determine the risk factors and co-morbidities associated with changes in renal function in 
HIV infected adults in South Africa. 
Methods: We conducted a retrospective study of 350 ART-naïve adult patients attending the 
King Edward VIII HIV clinic, Durban, South Africa.   Data was collected at baseline (pre-
ART), and at 6, 12, 18 and 24 months on ART.  Renal function was assessed in the 24 month 
period using the modification of diet in renal disease (MDRD) equation and was categorised 
into normal renal function (estimated glomerular filtration rate (eGFR ) ≥ 60), moderate renal 
impairment (eGFR 30-59), severe renal impairment (eGFR 15-29) and kidney failure (eGFR < 
15ml/min/1.73m2).  Generalised linear models for binary data were used to model the 
probability of renal impairment over the 5 time periods, controlling for repeated measures 
within participants over time.  Risk ratios and 95% confidence intervals were reported for each 
time point versus baseline. 
Results: The cohort was 64% female and 99% were Black  The mean age was 36.9±9.7 years.  
At baseline, 10 patients had hypertension, 6 had diabetes, 61 were co-infected with tuberculosis 
(TB) and 157 patients had a high body mass index (BMI) with 25.4% being categorised as 
overweight and 19.4% obese. The majority of the patients (59.3%) were normotensive.   At 
baseline the majority of the patients (90.4%) had a normal renal function (95% confidence 
intervals (CI):86%-93%), 7.0% (CI:5%-10%) had moderate renal impairment, 1.3% (CI:0%-
3%) had severe renal impairment, and 1.3% (CI:0%-3%) had kidney failure.  As BMI increased 
by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03 – 1.10) times.  The 
association of hypertension (HPT) with abnormal renal function was found to be insignificant, 
p>0.05.  The vast majority of patients were initiated on tenofovir disoproxil fumarate (TDF) 
(90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) (56.6%) 
or nevirapine (NVP) (43.4%). Seven patients of the 29 patients (24%) with baseline renal 
impairment, had persistent renal impairment at 24 months on ART while the eGFR of 13 
patients (44.8%) normalised at 24 months on ART.  
Conclusion: This study reports a low prevalence of baseline renal impairment in HIV-infected 
ART-naïve outpatients. An improvement in renal function after the commencement of ART 
has been demonstrated among this population.  However, the long-term outcomes of patients 
with HIV-related renal disease is not known.  
 






South Africa accounts for approximately 18 % of global human immunodeficiency virus (HIV) 
infections, with an estimated prevalence of  6.7 million HIV-infected people (1).  There are 
almost 1000 new HIV infections, the majority of which are heterosexually transmitted (2).  In 
an attempt to end the surge of  HIV plaguing the African continent, the Joint United Nations 
Programme on HIV/AIDS (UNAIDS), have established an ambitious but achievable target to 
have 90% of all people tested for HIV, and treated and virologically suppressed by 2020 (3).  
Providing antiretroviral treatment (ART) to all people living with HIV (PLHIV) irrespective 
of CD4 count can help prevent HIV-related illness, avert acquired immunodeficiency 
syndrome (AIDS)-related deaths and prevent new HIV infections (3). South Africa (SA) 
implemented the UNAIDS policy in September 2016 (4).   This universal access to ART for 
PLHIV is likely to lead to an increase in the burden of chronic diseases in SA as people are 
living longer with HIV (5). 
 
Stanifer et al.’s 2014 study has shown that chronic kidney disease (CKD) has been prevalent 
and at an increase in Sub-Saharan Africa with 24% of patients with hypertension, 18.9% of 
diabetes and 10% of HIV infected patients having co-morbid CKD (6).  The use of long-term 
medication for chronic illnesses can pose a threat to the kidneys and the use of ART is no 
exception (7-9).  Tenofovir disoproxil fumarate (TDF), a potentially nephrotoxic drug (10, 11), 
is widely utilised as first line ART in SA and screening for baseline renal dysfunction prior to 
TDF initiation is essential (12).  The SA ART guidelines recommend a serum creatinine and 
creatinine clearance at baseline (prior to ART initiation) and then at 3 months, 6 months, 12 
months and annually thereafter for patients on TDF (13).  
 
Our systematic scoping review has demonstrated a research gap on ART nephrotoxicity, 
particularly with TDF, as well as the long-term outcomes of renal function for patients on ART 
in South Africa.  This is of great concern because we do not know the burden of ART 
nephrotoxicity or morbidity that our population may experience.  Further, with the current 
health infrastructure, access to nephrologists and dedicated renal services are limited to a few 
tertiary hospitals.  In this study, we aim to determine the risk factors and co-morbidities 
associated with changes in renal function in HIV infected adults in South Africa. We anticipate 





and mortality of ART nephrotoxicity and influence the expansion of renal services offered in 





We conducted a retrospective study of 350 ART-naïve adult patients (18 years and older) 
attending the King Edward VIII HIV clinic, Durban, South Africa.  
 
Study population 
Our study population was ART naïve HIV-infected adult patients who presented to us from 
across KwaZulu-Natal seeking initiation of ART. We included patients who were initiated on 
ART from April 2010 to December 2013 and followed up over a 24 month period.  Patients 
already on ART who were transferred to the clinic were excluded.   
 
Data extraction 
Clinical data was extracted from medical records of patients attending the HIV clinic at King 
Edward VIII Hospital in the study period from April 2010 to December 2013.  To minimise 
selection bias, we selected clinical charts sequentially for ART naïve patients.  Data was 
collected at baseline (pre-ART), and at 6, 12, 18 and 24 months on ART.  Data collected 
included socio-demographics, clinical parameters (weight, height, body mass index, blood 
pressure, pulse, finger prick glucose, urine dipstick analysis), history of co-morbidities 
(hypertension, diabetes, tuberculosis, pregnancy), laboratory data (serum creatinine and 
estimated glomerular filtration rate) and the type of ART regimen.  We also documented 
patients who were lost to follow up.   
 
Outcome measures 
CKD was defined as either kidney damage or a glomerular filtration rate (GFR) of 
<60mL/min/1.73m2 for ≥ 3 months irrespective of cause (14).  Estimated GFR (eGFR) used in 
data analyses was calculated using the simplified modification of diet in renal disease (MDRD) 
equation without the ethnicity factor: eGFR (mL/min/1.73m2) = 175 × [Scr(µmol/L)/88.4]
-
1.154 × Age(years)-0.203 × (0.742 if female) (15) and was performed at the National Health 





correct for the use of µmol/L as the unit of measure for serum creatinine (15).  For this study 
we modified the staging of chronic kidney disease from that of the  Kidney Disease Outcomes 
Quality Initiative (KDOQI) of  the National Kidney Foundation (Table 3.1) (14) because the 
NHLS reports creatinine levels above 60µmol/L as >60µmol/L and does not specify the actual 
eGFR level.  For those patients who did not have a documented eGFR from the lab either 
because the age or gender was not documented on the laboratory request form, we calculated 
the value using the MDRD equation above, with the age and gender captured during data 
collection. Proteinuria detected on urine dipstick analysis refers to the presence of protein of 
1+ or more in the urine.   
 
TABLE 3. 1: STAGING OF CHRONIC KIDNEY DISEASE 
DESCRIPTION eGFR ml/min/1.73m2 
Normal renal function ≥60 
Moderate renal impairment 30 – 59 
Severe renal impairment 15 - 29 
Kidney failure < 15 
(needs dialysis) 
GFR – glomerular filtration rate 
An adaptation of the CKD classification of the KDOQI of National Kidney Foundation 
 
 As per the South African Hypertension Guidelines, hypertension (HPT) is defined as a 
persistent elevation of blood pressure(BP)  ≥140/90 (16).  The classification of HPT into 4 
categories was made in accordance with the JNC8 guidelines (Table 3.2) (17).  Body mass 
index (BMI) is an index of weight-for-height that is used to classify persons as underweight, 
normal, overweight or obese.  BMI is calculated as the weight (kilograms) / height (metres) ².  
Classification of BMI was based on that of the World Health Organisation (WHO) (Table 3.3) 











TABLE 3. 2: CLASSIFICATION OF HYPERTENSION 
Classification Systolic blood 
pressure (mmHg) 
 Diastolic blood 
pressure (mmHg) 
Normal <120 AND <80 
Prehypertension 120-139 OR 80-89 
Stage 1  140-159 OR 90-99 
Stage 2 ≥ 160 OR ≥ 100 
NB. BP should be categorised according to the highest level of BP whether systolic or diastolic. 
Classification as per JNC8 guidelines. 
 
TABLE 3. 3: CLASSIFICATION OF BMI 
Classification BMI 
Underweight <18.50 
Normal Range 18.50 – 24.99 
Overweight ≥ 25.00 
Obese ≥ 30.00 
BMI – body mass index = weight (kilograms) / height (meters). Classification as per WHO guidelines. 
 
Statistical Analysis 
IBM SPSS version 24 and Stata version 13 were used for data analysis.  To assess the effect of 
time on ordinal outcomes, the outcomes were first categorised into binary variables indicating 
the presence or absence of a condition.  eGFR categories were collapsed into normal (eGFR ≥ 
60), versus renal impairment (moderate to kidney failure, eGFR < 60).  Blood pressure 
categories were dichotomised to normal versus hypertension – the latter included pre-
hypertension.  Generalised linear models for binary data were used to model the probability of 
renal impairment over the five time periods, controlling for repeated measures within 
participants over time.  Risk ratios and 95% confidence intervals were reported for each time 
point versus baseline.  A p value of <0.05 represented statistical significance.  
 
Ethical approval  
Full ethical approval was obtained from the Biomedical Research and Ethics Council (BREC) 









The baseline characteristics of the 350 patients included in the analysis are illustrated in Table 
3.4.  Their mean age was 36.9 years with a standard deviation of 9.7 years.  The range was 
from 18 years to 72 years.  The cohort was 64% female and 99% were African.  Of the women, 
16% were pregnant at baseline.  Also at baseline, 10 patients had hypertension, 6 had diabetes 
and 61 were on tuberculosis (TB) treatment.  At baseline, 157 patients had a high BMI with 
25.4% being categorised as overweight and 19.4% obese (Figure 3.1).  Due to a lack of 
documentation of either the weight or height or both, 20 patients did not have a BMI 
documented at baseline.  The majority of the patients (59.3%) were normotensive while 24.1% 
were classified as pre-HPT, 9.9% as stage 1 HPT and 6.7% as stage 2 HPT (Figure 3.2).  
 
TABLE 3. 4: BASELINE DEMOGRAPHICS 






Gender Female 224 64.0 0.59 – 0.69 
Male 126 36.0 0.31 – 0.41 
Race African 348 99.4 0.98 – 1.00 
Indian 0 0.0 0.0 
White 0 0.0 0.0 
Coloured 2 0.6 0.00 – 0.02 
HPT No 340 97.1 0.95 – 0.98 
Yes 10 2.9 0.02 – 0.05 
DM No 344 98.3 0.96 – 0.99 
Yes 6 1.7 0.01 – 0.04 
TB No 288 82.5 0.78 – 0.86 
Yes 61 17.5 0.14 – 0.22 
PREGNANT (women) No 188 83.9 0.86 – 0.93 
Yes 36 16.1 0.07 – 0.14 










FIGURE 3. 1: BASELINE BMI CATEGORIES 
 
Underweight – BMI < 18.50; Normal – BMI 18.50 to 24.99; Overweight – BMI ≥ 25; Obese – BMI ≥ 30. 
 
FIGURE 3. 2: BASELINE HPT CATEGORIES 
 
Normotensive – BP <120 and <80; Pre HPT – BP 120 to 139 or 80 to 89; Stage 1 – BP 140 to 159 or 90 to 99; 
Stage 2 – BP ≥ 160 or ≥ 100.  Measurement of BP in mmHg. 
 
Baseline renal function 
At baseline, the majority of the patients had a normal renal function 90.4%, [95% confidence 































3%) had severe renal impairment, and 1.3% (CI:0%-3%) had kidney failure (Table 3.5).  The 
eGFR for 49 patients was not documented at baseline.  Relative to baseline the risk of 
developing renal impairment decreased at the subsequent time points (Appendix E).  At 6 
months the risk of having renal impairment was 82% (CI:5%-72%) lower than baseline, at 12 
months it was 56% (CI:22%-87%) lower, at 18 months 72% (CI:10%-77%) lower and at 24 
months the risk was 49% (CI:29%-91%) lower than baseline.   
 


























































































TOTAL 301 114 189 147 223 
Missing data at various time points as data was not documented at these times possibly because clinicians were 
attending to large clinic numbers with a poorly kept paper filing system and these routine checks were missed.   
 
Appendix F demonstrates the characteristics of the 29 patients with baseline renal impairment 
and depicts the trend of the eGFR over various time points.  Of those patients with abnormal 





co-infected with TB while one patient had HPT.  The average age of the 29 patients was 45 
years.  Seven patients of the 29 patients (24%) with baseline renal impairment, had persistent 
renal impairment at 24 months.  Eight of the 29 patients did not have an eGFR done at 24 
months.  One patient was lost to follow up at 24 months.  The eGFR of 13 patients (44.8%) 
normalised at 24 months. 
 
In 2010, fixed dose combinations were unavailable in the public sector therefore patients were 
initiated on individual antiretroviral agents.  The vast majority of patients were initiated on 
TDF (90.6%), in combination with lamivudine (3TC) (100%) and either efavirenz (EFV) 
(56.6%) or nevirapine (NVP) (43.4%).  Twenty-three of the 29 patients with baseline renal 
impairment (eGFR’s < 60ml/min/1.73m2), were commenced on a TDF based regimen.  Of the 
10 patients with a baseline eGFR <50ml/min/1.73m2 who were commenced on TDF, 7 had a 
normalisation of eGFR by 24 months while three experienced a deterioration in renal function. 
Two of the patients had TDF discontinued at 18 months and replaced with ABC.  The 
remaining patients with renal impairment were either initiated on abacavir (ABC) (3 patients), 
zidovudine (AZT) (2 patients) or stavudine (D4T) (1 patient).  Fourteen of the 36 pregnant 
women were initiated on AZT whilst the remaining 22 were initiated on TDF.  The remaining 
patients were initiated on either D4T, AZT or ABC by the attending clinician as first line 
treatment with no reason specified.  Figure 3.3 demonstrates this distribution of ART at 
baseline. 














TDF – tenofovir, EFV – efavirenz, AZT – zidovudine, ABC – abacavir, D4T – stavudine. 
All 350 patients were on lamivudine (3TC) at baseline in combination with 2 other ART. 
 
Risk factors associated with abnormal renal function 
The factors tested for association with abnormal renal function were age group, time, BMI, 
hypertension.  The factors which remained significant in the model are shown in Appendix G 
and summarised in Table 3.6.   
 
TABLE 3.6. RISK FACTORS ASSOCIATED WITH ABNORMAL RENAL FUNCTION 
Variables Risk Ratio P value 95% confidence 
interval 
Time – 6 months 0.19 0.018 0.48 – 0.75 
             12 months 0.40 0.007 0.21 – 0.78 
             18 months 0.24 0.005 0.85 – 0.65 
             24 months 0.42 0.002 0.24 – 0.73 
    
BMI 1.06 0.000 1.03 – 1.09 
    
HPT 1.89 0.194 0.72 – 4.95 
    
Age – 30 to 49 years 2.51 0.128 0.77 – 8.22 
           ≥ 50 years 6.82 0.003 1.90 – 24.54 
    
 
 
Compared to those under 30 years old, there was no significant difference in renal impairment 
in those aged 30 to 49 years, p>0.05 (CI: 0.77 – 8.22) while those aged ≥50 years were 6.8 (CI: 
1.90 – 24.54) times more likely to develop renal impairment, p<0.05.   Time still remained a 
significant predictor.  As time increased, so the risk of abnormal renal function decreased.  As 
BMI increased by one unit, the risk of renal impairment increased by 1.06 (CI: 1.03 – 1.10) 
times.  The association of HPT with abnormal renal function was found to be insignificant, 
p>0.05.  A total of 21 patients (6%) were lost to follow up over the two years and 94% were 
retained in care (Table 3.7).  Of those patients who were lost to follow-up, there was no 









TABLE 3.7. LOST TO FOLLOW-UP 










6 months 2 (0.6%), CI: 0.00-0.02 348 (99.4%), CI: 0.98-
1.00 
12 months 2 (0.6%), CI: 0.00-0.02 348 (99.4%), CI: 0.98-
1.00 
18 months 9 (2.6%), CI: 0.01-0.05 341 (97.4%), CI: 0.95-
0.99 
24 months 8 (2.3%), CI: 0.01-0.05 342 (97.7%), CI: 0.95-
0.99 
 
Urine dipstick analysis 
Only 5 patients in the entire cohort had urine dipsticks performed at various time points (3 at 
baseline, 1 at 6 months and 1 at 12 months).  The test strip was positive for proteinuria in 4 out 
of the 5 patients (80%) and 3 out of the 4 patients (75%) with proteinuria were on a TDF based 
regimen with a normal eGFR.  The remaining patient had renal impairment and was on an ABC 




We aimed to determine the risk factors and co-morbidities associated with changes in renal 
function in an adult cohort with HIV in SA. The cohort was mainly female and a large 
proportion of patients were either pregnant or co-infected with TB.  The prevalence of renal 
impairment at baseline was found to be relatively low.  Females predominated with baseline 
renal impairment and the majority of the patients were co-infected with TB.  Of those patients 
with baseline renal impairment, the majority had a normalisation of their eGFR by 24 months.  
The risk of developing renal impairment decreased over the two year period while patients 
were on ART.  Risk factors found to be significant for renal impairment were older age, p<0.05 





significantly, p>0.05.  TDF was the ART of choice for ART initiation along with 3TC and 
either NVP or EFV in keeping with South African National ART guidelines (13).  Surprisingly, 
one third of patients with baseline renal impairment were initiated on a TDF based regimen in 
contravention of the standard ART guidelines.  These guidelines state that TDF should not be 
initiated in patients with an eGFR of <50 ml/min/1.73m2.  This probably reflects the practice 
in clinics that may be under-staffed where errors may have a tendency to occur. 
 
Similar studies conducted in South Africa showed a low prevalence of baseline renal 
impairment in an HIV-infected cohort (12, 19, 20) and some showed the improvement in eGFR 
after starting ART (19, 21, 22).  Similar findings were noted in an African study by Reid et al. 
carried out in Mozambique and Zimbabwe (23).  As HIV has been shown to have a direct renal 
pathogenic role (24, 25), we can deduce that treating the disease with ART diminishes the renal 
pathogenic effect.  However, there is a lack of information on the long term outcomes of renal 
disease in HIV-infected patients.  Not all our patients experienced a resolution in their renal 
function as described earlier.  Our cohort comprised mainly Black patients and therefore we 
were unable to compare the renal function of different ethnicities.  Consensus regarding gender 
as a risk factor for renal dysfunction could not be determined, as some studies found women to 
be at greater risk (19, 26) whilst others found men to be at greater risk (20).  Older age has been 
documented in numerous studies including ours as a risk factor for renal impairment (19, 20, 
27).  A low CD4 count, high viral load and low haemoglobin are other variables found to be 
associated with a lower eGFR (12, 19, 20, 27).  We did not assess these variables in our study.   
 
A high BMI has been documented in international literature as a modest risk factor for renal 
impairment over time (27). To the best of our knowledge, this is the first South African study 
to demonstrate BMI as a risk factor associated with changes in renal function in an HIV-
infected cohort.  This is a significant finding as a high BMI is also a risk factor for other chronic 
diseases such as HPT, diabetes and cardiovascular disease (28, 29) which in turn are risk factors 
for CKD (6).  Although we did not find a significant link between HPT and renal impairment, 
this has been observed in other studies (26, 27).  A possible explanation for our findings could 
be the duration we collected data (2 years) and ethnicity (our cohort mainly Black),  whilst in 
the other studies the duration was 96 weeks and 31 months respectively in predominantly white 






Several studies have described TDF associated nephrotoxicity as a pattern of renal injury 
involving the proximal renal tubule sometimes with Fanconi syndrome occurring together with 
a decreased renal function (7, 30).  They recommend monitoring of renal function to prevent 
these outcomes (10, 30, 31).  The South African ART guidelines recommend monitoring of 
renal function with urine dipsticks, a serum creatinine and eGFR levels at baseline, 6 months, 
12 months and annually thereafter for patients on TDF (13, 32).  The rate of adherence to these 
guidelines is not known.  In our study we found missing serum creatinine and eGFR levels at 
6 months, 12 months and 24 months.  A possible explanation for this is that clinicians were 
attending to large clinic numbers with a poorly kept paper filing system and these routine 
checks were missed.  In addition, clinicians were missing the 12 month serum testing because 
they calculated this test as one year from the 6 month blood test hence the blood was taken at 
18 months.  Of those patients initiated on TDF with an eGFR < 50 ml/min/1.73m2, only a few 
patients had a deterioration in renal function resulting in the discontinuation of TDF.  Most 
likely this is because the majority had a reversible cause for the renal impairment, for example 
dehydration rather than actual renal disease.     
 
Urine analysis is important to detect proximal renal tubular damage in patients on TDF as well 
as undiagnosed HIVAN, yet they were rarely performed in our clinic setting,  again, possibly 
due to large volumes of clinic patients combined with staff shortages and limited ablution 
facilities.   Fabian et al. showed that urinary abnormalities were common in HIV-infected, ART 
naïve outpatients and recommended that routine urinary screening of all new patients at ART 
clinics should be practiced (33).  However, urine dipstick usage as a solitary screening tool is 
a topic with much debate, as research both locally and internationally suggests their poor 
validity in detecting proteinuria (20, 34).  
 
A study conducted in South Africa by Han et al. showed that microalbuminuria alone could be 
an early marker for HIV associated nephropathy (HIVAN) (35).  HIVAN is the most common 
histology seen on renal biopsy in South African patients (21, 22).  HIVAN is commonly found 
in Black patients who seem to have a genetic predisposition for the disease (36) and Kasembelli 
et al. documented this finding in a South African cohort (37).  Therefore, by deferring urine 
analysis, we may be missing an opportunity to detect early HIVAN in our predominantly Black 
high-risk cohort.  The best method for urine screening is not known (6).  Relying solely on 
serum creatinine levels and eGFR is inappropriate for this group of patients as HIVAN can 





A strength of this study we feel is that we had a good sample size of 350 patients and a good 
representation of the profile of patients who are currently attending ART clinics across SA.  
The main limitation of the study would be that of missing data, for example the weight, height, 
blood pressures and baseline serum creatinine were not documented in some patients.  Another 
limitation is that renal impairment that occurred between the data collection months was not 
captured therefore episodes of acute renal impairment were not ascertained.  Lastly, we cannot 
comment on the diagnosis of those with persistent renal impairment at 24 months as renal 
biopsies were not done. 
 
Conclusion 
This study shows a low prevalence of baseline renal impairment among HIV-infected ART 
naïve outpatients and an improvement in renal function after the commencement of ART.  This 
highlights the possibility of HIV being the likely cause of the renal impairment at baseline or 
that there is a beneficial effect of ART on early HIVAN.  Caution should be exercised when 
excluding TDF as an option at initiation due to renal impairment as most patients have a 
reversible cause for the renal dysfunction which can be corrected before ART initiation.  
Ultimately, TDF as part of a fixed dose combination is a once daily dose which greatly 
improves adherence.   Long-term outcomes of patients with HIV-related renal disease are not 
known.  BMI has been associated with the development of renal impairment in an HIV-infected 
cohort.  With the recently introduced universal access to ART in SA, we anticipate the affliction 
of chronic diseases and their complications including renal disease to increase. Therefore, 
prospective studies targeting patients with HIV-related renal disease are needed in South 
Africa. Research on the most cost-effective and accurate urine diagnostics are also needed to 
detect early renal disease.  Urine microalbumin screening is not routinely practiced at ART 
clinics despite being found to be an early marker for HIVAN (35).  We need to improve and 
reinforce optimal primary care in our clinics including regular BP monitoring, anthropometry 
and urine analysis.  Lastly, we need to explore the influence of a high BMI in our HIV-infected 
patients and its link to CKD and other chronic diseases in order to promote a healthy lifestyle 
and dietician services as part of holistic management of our patients (an area often neglected 
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CHAPTER 4: SYNTHESIS: SUMMARY, DISCUSSION, CONCLUSION AND 
RECOMMENDATIONS 
 
This chapter presents a summary of our research findings, and assesses the strengths and limitations of 
this study. It also presents the conclusions, recommendations for improvement of existing services and 
offers suggestions for further research. 
 
4.1 Background 
The main aim of this study is to portray the current stance on the renal manifestations of HIV in SA in 
the era of ART.  The significance of this study cannot be denied as South Africa carries the global 
burden of HIV infection and the rollout of ART has now been extended to all HIV infected 
individuals irrespective of CD4 count or clinical stage (1).   As early as 2010, a South African study 
demonstrated an increase in the prevalence of CKD in HIV-infected individuals (2).  We anticipate 
the domino effect of universal ART access to be further increases in the prevalence of CKD as well as 
HIV-related kidney diseases as HIV transforms into a disease of chronicity.   
 
Recently, there has been an upsurge of research and publications on the topic (3-8), therefore the 
contribution of a systematic scoping review gains importance and relevance by demonstrating the 
current data in order to identify research gaps and suggest novel ideas for future research.  The 
retrospective chart review gives an overview of what is being practised at an HIV clinic as well as a 
description of the presentation of renal impairment in an HIV cohort.  Comparing these findings with 
that of the systematic scoping review, will unravel areas where research is lacking as well as indicate 
domains in clinical practice that need improvement or refinement.  Ultimately, the conclusions drawn 
will benefit the millions living with HIV in SA and particularly those with renal disease.   
 
4.2 Key Findings of the Study 
The research questions needed answers on the gaps in research on HIV-related renal diseases in SA and 
the current volume of HIV-related renal manifestations reported in SA.  Our study shared similarities 
with other studies demonstrating that the prevalence of baseline renal impairment in HIV-infected 
patients is low (8-10) and that renal function improves with ART (5, 11).  However, the long-term 
effects of ART on renal disease is not known and the morbidity and mortality of those with CKD and 
HIV-related renal disease is not well documented.  HIV cohorts in SA comprise mainly Black 
individuals who are at high risk for developing HIVAN due to a possible genetic predisposition to the 
disease (12).  HIVAN was also the most common histological finding on renal biopsy (5, 11).  HIVAN 
can occur with only microalbuminuria and a normal renal function (4).  Therefore, urine dipstick 
analysis is essential for the early detection of renal impairment.  The best method for urine protein 





a clinic level; therefore we could be missing patients with undiagnosed renal disease.  We do not know 
the actual prevalence or incidence of HIV-related kidney diseases and CKD in SA.  We believe that our 
chart review was the first South African study to link a high BMI as a risk factor for renal impairment.   
  
4.3 Strengths of the study 
The systematic scoping review focussed on studies carried out in South Africa, a hyper-HIV burdened 
country.  The strength of a systematic scoping review is undoubtedly its rigorous methodology. This 
included parallel screening of abstracts and full articles by two screeners and methodology quality 
assessment of included studies. Kappa statistics was employed to estimate the degree of agreement 
among screeners. The study team utilised Arksey and O’Malley’s scoping review framework (13) and 
adapted it to suit the study based on recommendations made by Levac et al. in 2010 (14).  This 
framework was best suited to answer the research questions as it involved ‘mapping’, a process that 
summarises a range of evidence to convey the breadth and depth of the research topic (14).  It is 
systematic, transparent and replicable (15).  This type of review is advantageous in that it provides a 
preliminary assessment of the potential size and scope of available research literature on a particular 
topic and identifies the nature and extent of research evidence (15).  Ultimately, it is able to inform 
researchers if a full systematic review or primary research study should be undertaken (15).  Even 
though renal function improves with ART, the long-term outcomes of renal disease for patients on ART 
is not well documented.  
 
In order to ensure eligibility of the research question for this research method, the team formulated a 
data extraction table based on the PICO model (16).  Bias was reduced throughout the scoping review 
process. Screening of literature was conducted by two independent researchers with a third for resolving 
discrepancies.  In addition, all included studies were assessed for quality by use of the tried and tested 
mixed methods appraisal tool (17).  Systematic reviews form part of evidence-based medicine (EBM) 
research methods, considered the gold standard of study design and which perch at the very top of the 
hierarchy of the evidence pyramid (18, 19).   
 
The main strength of the retrospective chart review is that is utilises secondary data, that is data that has 
already been already collected for purposes other than research.  This is advantageous as the data is 
readily accessible, economical, improves understanding of the problem and provides a basis for 
comparison of the data collected. A representative sample size of 350 medical records of patients 
attending the ART clinic in eThekwini, KwaZulu-Natal was used. The data was obtained from a high 
HIV pandemic region, eThekwini, KwaZulu-Natal is known as the epicentre of the HIV epidemic. The 
demographic profile of the study cohort is representative of other ART clinics across South Africa.   
Overall, the results of the chart review will impact and improve patient care as they unravel errors in 





4.4 Limitations of the study 
Overall, the study has made significant findings.  Nonetheless, there are some limitations that must be 
acknowledged.     Most of the evidence obtained from the scoping review was derived from 
observational studies.  Even though observational studies are an important source of data when 
randomised controlled trials are unavailable, they are prone to bias (21).    
 
 With regards to the retrospective chart review, there are a few limitations.  Firstly one of the 
unavoidable limitation is that of missing data from the clinic charts. For example the weight, height, 
blood pressure, urine dipstick and baseline serum creatinine were not documented in some patients at 
the various data collection times.  Episodes of acute renal failure that may have occurred between the 
data collection points were not documented.  Though this missing data was not substantial it could 
possibly influence the results obtained.  Lastly, we cannot distinguish between or account for the 
incidence of TDF nephrotoxicity versus HIV nephropathy at 24 months, as the study did not 
document renal biopsy or ultrasound findings in the cohort.   
 
4.5 Conclusions 
This study demonstrates the current stance on the renal manifestations of HIV in the era of ART in 
South Africa and illustrates the deficiencies in knowledge and their implications for the future.  The 
findings of the study are in keeping with that of international literature. Universal access to ART for all 
HIV-infected South Africans will likely result in an increase in chronic diseases namely HIV, HPT, 
CKD and diabetes.  The impact on the current health infrastructure that this strategy will have is 
unknown.  There is a shortfall in knowledge and statistics on the incidence and prevalence of CKD, 
HIV-related renal diseases and ART related nephrotoxicity in SA currently.   Furthermore, there is a 
deficiency in evidence on the long-term morbidity and mortality of HIV-infected patients with renal 
disease.  This information is imperative to assist policymakers in management decisions as well as 
enhancing the health infrastructure to support patients with CKD.  There is a lack of dedicated CKD 
clinics and specialist renal services particularly in the rural settings (22) as well as a shortage of 
nephrologists in SA (23).   Though urine diagnostics are vital for the early detection of renal disease, it 
is not being routinely performed.  The current South African ART guidelines also make no clear 
guidance on exactly when and how this test should be performed.  
 
4.6 Recommendations 
Based on the study conclusions, the following recommendations are suggested:   
1. Renal registries should be established which will assist with much needed statistics on the 
morbidity and mortality of both HIV-related and non-related renal disease as well as ART 





2. The National Department of Health should establish CKD clinics in rural areas and nephrology 
outreach services. 
3. Clear guidelines for the use of urine dipstick analysis as routine screening for all patients 
attending ART clinics should be included in the National ART guidelines.  The 
recommendation is for urine dipstick analysis at baseline, 3 months and 6 monthly thereafter. 
4. Patients and clinical staff should be educated (and therefore empowered) about the importance 
of urine dipstick analysis, BP and glucose monitoring and anthropometry, which will ensure 
these routine screening tests are regularly performed in overburdened facilities. 
5. Training on adherence to guidelines. 
  
4.7 Dissemination of Research 
Based on the study findings and the flaws detected by the chart review regarding poor adherence to 
ART guidelines, we recommend training all clinic staff timeously about ART guidelines and routine 
checks that must be performed at clinic visits.  The conclusions from our research will be shared with 
the hospital management as well as the Provincial Department of Health.  Both manuscripts will be 
published in reputable journals to further disseminate information. 
   
4.8 Future Studies 
Based on the study findings, the following areas of research are recommended: 
1.  More research to be carried out in rural areas where access to healthcare and laboratories is not 
easily accessible.   
2. Comparative studies to determine the differences in renal manifestations between HIV infected 
males and females, preferably in rural settings, are recommended.  More males must be 
recruited to participate in research. 
3. Research into cost effective methods for urine screening - microalbuminuria versus proteinuria 
as well as the development of an algorithm for screening and confirming proteinuria. 
4. Comparative studies looking at microalbuminuria versus proteinuria on urine dipstick analysis 
as a more cost effective and accessible marker for early HIVAN. 
5. A prospective randomised controlled trial investigating diagnosis options for HIVAN.   
6. Cohort study focussing on TDF nephrotoxicity and its long term renal outcomes. 
7. A survey to determine the prevalence of renal disease and HIV-related renal disease in South 
Africa in order to strengthen primary healthcare services to reduce the burden of CKD. 
8. A cohort study to determine the link between high BMI and renal impairment (to confirm the 
findings of our study) – vicious circle as it contributes to other chronic disease which are also 
risk factors for CKD. 
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A.3 APPENDIX C- List of studies included for full article screening and reviewers’ 
responses 
Author and Date Response: Reviewer 1 Response: Reviewer 2 
Arendse et al., 2011 No No 
Brennan et al., 2011 No Yes 
Fabian et al., 2009 Yes Yes 
Fabian et al., 2013 Yes Yes 
Fabian et al., 2015 No Yes 
Franey et al., 2009 Yes Yes 
Kamkuemah, 2013 Yes Yes 
Kamkuemah et al., 2015 Yes Yes 
Kasembelli et al., 2015 Yes Yes 
Madala et al., 2014 No Yes 
Okpechi et al., 2010 No No 
Stanifer et al., 2014 No No 
Vachiat et al., 2013 Yes Yes 
Van Deventer et al., 2008 Yes Yes 
Wearne et al., 2012 Yes Yes 
Wensink et al., 2015 Yes No 
Gerntholz et al., 2006 No No 
Han et al., 2006 No No 
Okpechi et al., 2010 No No 
Van Rensburg et al., 2009 No No 
Madala et al., 2012 No No 
  
 
             Expected 






  80.95%      49.66%     0.6216     0.2143       2.90      0.0019 
 
                 | Controls               | 
Cases            |   Exposed   Unexposed  |      Total 
-----------------+------------------------+------------ 
         Exposed |         9           1  |         10 
       Unexposed |         3           8  |         11 
-----------------+------------------------+------------ 
           Total |        12           9  |         21 
 
McNemar's chi2(1) =      1.00    Prob > chi2 = 0.3173 
Exact McNemar significance probability       = 0.6250 
 
Proportion with factor 
        Cases       .4761905 
        Controls    .5714286     [95% Conf. Interval] 
                   ---------     -------------------- 
        difference -.0952381     -.3250218   .1345456 
        ratio       .8333333      .5826548   1.191863 
        rel. diff. -.2222222     -.7037382   .2592937 
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A.5 APPENDIX E- Risk of Developing Renal Impairment over time 
Generalized linear models                          No. of obs      =       973 
Optimization     : MQL Fisher scoring              Residual df     =       968 
                   (IRLS EIM)                      Scale parameter =         1 
Deviance         =  401.4853798                    (1/df) Deviance =  .4147576 
Pearson          =  972.9991345                    (1/df) Pearson  =  1.005164 
  
Variance function: V(u) = u*(1-u/1)                [Binomial] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   BIC             = -6258.726 
 
                              (Std. Err. adjusted for 348 clusters in STUDYNO) 
------------------------------------------------------------------------------ 
             |             Semirobust 
  GFR_binary | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        time | 
   6 months  |   .1820932   .1277103    -2.43   0.015     .0460582    .7199133 
  12 months  |   .4393359   .1536724    -2.35   0.019     .2213403    .8720329 
  18 months  |   .2824302   .1451236    -2.46   0.014     .1031646    .7731993 
  24 months  |   .5142902   .1508526    -2.27   0.023     .2894223    .9138699 
             | 










A.6 APPENDIX F- Followup of eGFR of patients with baseline renal impairment 
FILE  BASELINE 6MONTHS 12MONTHS 18MONTHS 24MONTHS 
49/11 
72yrs 






ART TDF,3TC,EFV     
205/11 
53yrs 











ART TDF,3TC,EFV     
568/10 
51yrs 




ART TDF,3TC,EFV     
275/11 
32yrs 






ART TDF,3TC,EFV     
371/11 
36yrs  








ART TDF,3TC,EFV     
567/11 
59yrs 






ART TDF,3TC,EFV     









ART TDF,3TC,EFV     
587/11 
56yrs 







ART TDF,3TC,EFV     
788/11 
40yrs 





ART TDF,3TC,EFV     
1033/11 
60yrs 




















ART TDF,3TC,NVP TDF,3TC,EFV    
1145/11 
50yrs 









ART TDF,3TC,EFV     
819/10 
33yrs 
eGFR 3.68 4.01 nd LTFU LTFU 
Male, 
HPT 













ART TDF,3TC,EFV   ABC,3TC,EFV  
150/12 
42yrs 








ART TDF,3TC,NVP   AZT,3TC,Aluvia  
341/12 
51yrs 




ART AZT,3TC,EFV ABC,3TC,EFV    
346/12 
49yrs 





ART ABC,3TC,EFV     
416/12 
46yrs 







ART TDF,3TC,EFV    FDC 
       
475/12 
30yrs 





















ART TDF,3TC,EFV  FDC   
431/12 
69yrs 























ART TDF,3TC,EFV     
600/12 
44yrs 







ART TDF,3TC,EFV    FDC 
1039/10 
40yrs 







ART AZT,3TC,NVP     
1266/10 
49yrs 
eGFR 24.22 nd 24.82 nd nd 
Female, 
TB 













ART TDF,3TC,EFV     
494/10 
26yrs 







ART D4T,3TC,EFV  D4T,3TC,NVP   
1336/10 
49yrs 






ART TDF,3TC,EFV     
1339/10 
25yrs 
eGFR 6.24 >60 
110.06 






ART TDF,3TC,EFV     
Nd – not done, ART – antiretroviral treatment, TB – tuberculosis, BMI – body mass index, LTFU – lost to follow 











A.7 APPENDIX G- Risk factors and co-morbidities associated with abnormal renal 
function 
Generalized linear models                          No. of obs      =       972 
Optimization     : MQL Fisher scoring              Residual df     =       963 
                   (IRLS EIM)                      Scale parameter =         1 
Deviance         =  353.6712349                    (1/df) Deviance =  .3672598 
Pearson          =  991.4235583                    (1/df) Pearson  =  1.029516 
  
Variance function: V(u) = u*(1-u/1)                [Binomial] 
Link function    : g(u) = ln(u)                    [Log] 
 
                                                   BIC             = -6271.148 
 
                              (Std. Err. adjusted for 348 clusters in STUDYNO) 
------------------------------------------------------------------------------ 
             |             Semirobust 
  GFR_binary | Risk Ratio   Std. Err.      z    P>|z|     [95% Conf. Interval] 
-------------+---------------------------------------------------------------- 
        time | 
   6 months  |   .1905768    .133623    -2.36   0.018     .0482225    .7531656 
  12 months  |   .4020471   .1349437    -2.71   0.007     .2082468    .7762033 
  18 months  |   .2356236   .1224814    -2.78   0.005     .0850646    .6526627 
  24 months  |   .4218433   .1191978    -3.05   0.002     .2424556    .7339563 
             | 
         BMI |   1.060231   .0130867     4.74   0.000      1.03489    1.086194 
             | 
         HPT | 
        yes  |   1.891108   .9282237     1.30   0.194     .7226302     4.94899 
             | 





          2  |   2.512881   1.519828     1.52   0.128      .767985     8.22226 
          3  |   6.822283    4.45519     2.94   0.003     1.896991    24.53546 
             | 
       _cons |   .0066735   .0045581    -7.33   0.000     .0017497    .0254532 
------------------------------------------------------------------------------ 
 
 
 
